

Published in final edited form as:

Nat Genet. 2021 October 01; 53(10): 1405–1414. doi:10.1038/s41588-021-00936-6.

The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant

A full list of authors and affiliations appears at the end of the article.

These authors contributed equally to this work.

Abstract

The COVID-19 pandemic has radically affected the world since 2020. Spain was one of the European countries with the highest incidence during the first wave. As a part of a consortium to monitor and study the evolution of the epidemic, we sequenced 2,170 samples, mostly diagnosed before lockdown measures. Here we identified at least 500 introductions from multiple international sources; and documented the early rise of two dominant Spanish Epidemic Clades (SECs), likely amplified by superspreading events. Both SECs were closely related to the initial Asian variants of SARS-CoV-2 and spread widely across Spain. We inferred a substantial reduction in the effective reproductive number of both SECs due to public-health interventions ($R_e < 1$), also reflected in the replacement of SECs by a new variant over the Summer of 2020. In summary, we reveal a significant difference in the initial genetic makeup of SARS-CoV-2 in Spain compared to other European countries and show evidence to support the effectiveness of lockdown measures in controlling virus spread, even for the most successful genetic variants.

The new coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) emerged in China in October/November 2019¹ and by the end of March of 2020 it was present in most countries of the world. The World Health Organization declared the new disease as a pandemic on 11th March 2020. Spain suffered a severe epidemic with the first case reported on 29th January 2020², and an accumulated number of 249,659 cases by 1st July 2020, including 28,363 fatalities³. Furthermore, a nationwide seroprevalence study showed that only one in ten cases of infection by SARS-CoV-2 were diagnosed and reported in that period⁴, suggesting that the total number of

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: <https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms>

*Corresponding authors (mireia.coscolla@uv.es, fernando.gonzalez@uv.es, icomas@ibv.csic.es).

** A full list of authors can be found at the end of the article

Author contributions

IC, FGC and MC conceived the work. GAG, GDA and SJS set up the bioinformatics environment and the analysis pipeline. MGL, ACO, PRR and NGG analyzed the data. ACO and MGL wrote the first version of the draft. AO, EM, AEB, AN, DGV, LPL, MH, JS, CLC, MT, MPBE, NGJ, GM, LMP, PRH, MAB, NGG, LRR, MTP, IGN, JFP, AS sequenced genomes. GCE, MMR, LPV, JMM, RMM, MDTB, JAL, VGG, ARV, DN, EA, IT, ACB, SHC, MLCR, AR, AT, AMB, JMNM, IPC, SSG, BFE, CGC, BPB, ITP, AC, VM, MPG, LRF, JLP, JA, JJCA, MCPG, JAB, NR, JLLH, MAZ, MPR provided samples. IC, FGC, MC, ACO, MGL, SD and DGV critically reviewed and contributed to the final version of the paper. Rest of the SeqCOVID-Spain consortium members provided samples, clinical and epidemiological information.

Competing interests

The authors declare no competing interests.

infections has been vastly underestimated. Spain ordered a series of non-pharmaceutical intervention (NPI) measures including a general lockdown on 14th March 2020⁵, later applied by many other countries, and was successful in reducing infection rates by the end of May 2020⁶. Despite these measures, almost 30,000 individuals died during the first wave of the epidemic (until 14th May 2020), and a second wave of COVID-19 was beginning to emerge by the beginning of July 2020⁷.

Despite the high incidence of infection across the country, some regions had significantly higher incidence than others. Genomic epidemiology and phylodynamics^{8–10} offer a unique opportunity to understand the early events of the epidemic at the global, regional and local levels, to track the evolution of the epidemic after its initial stages and to quantify the impact of lockdown measures on the genetic variants of the virus. However, there are challenges and caveats that prevent the use of pathogen genomes as the sole source of interpretation. While there is now a large number of SARS-CoV-2 sequences deposited in GISAID¹¹, there are still important unsampled areas of the world, including some that played an important role in the initial spread of the epidemic. In addition, the virus spreads faster than it evolves^{12,13} which limits the resolution of phylogenetic and phylodynamic analyses¹⁴. Finally, despite important efforts by sequencing consortiums, only a fraction of the total number of infections has been sequenced. Nevertheless, genomic epidemiology has played an important role in understanding the global and local epidemiology of COVID-19^{15–17}.

After the pandemic was declared in Spain, we assembled the National Consortium of genomic epidemiology of SARS-CoV-2 (<http://seqcovid.csic.es/>). This established a unique network incorporating more than 50 hospitals and scientific institutions across the country to collect clinical samples and epidemiological information from COVID-19 cases. Here we present the results of this nation-wide effort. We were able to sequence 12% of the reported cases before the national lockdown, and 1% of the reported cases of the first wave when lockdown measures ended (14th May 2020), including samples of SARS-CoV-2 across Spain in the early months of the pandemic (February-May 2020). Using a combination of pathogen genomics, phylogenetic tools, clinical and epidemiological data we have been able to dissect the very early events in the dispersion of SARS-CoV-2 throughout Spain, as well the evolution of the virus during the exponential phase and after the lockdown. We document simultaneous introductions into the country from multiple sources. We show that up to 40% of cases were caused by two Spanish epidemic clades, named SEC7 and SEC8. Seven other Spanish epidemic clades were detected but their role was minor, probably because they were introduced relatively close to the lockdown and had no opportunities for a rapid exponential expansion as the initial two clades had. In contrast to clades from other European countries, these SECs belong to early lineages in the epidemic (A in Pango, 19B in NextStrain). We also show that the reproductive number, R_e , of the most successful Spanish epidemic clades quickly declined after the implementation of lockdown measures, and they were completely absent from samples taken in July-September 2020. Our results suggest that the most successful variants were those associated with earlier introductions, but also that their success may have depended on the synergy between superspreading events and high mobility. These results also show the effectiveness of lockdown measures in controlling the virus spread and eliminating established successful epidemic clusters from circulation.

SARS-CoV-2 was introduced multiple times from multiple sources

Our dataset consists of 2,170 sequences from Spain, collected under ethical approval, from 25th February to 22nd June 2020, coinciding with the initial phases of the COVID-19 pandemic in the country (Figure 1a). The most populated Spanish regions were sampled, resulting in a dataset with sequences representing 16 of the 17 administrative regions in which the country is divided (Figure 1b). 1,962 out of the 2,170 (90.4%) samples analyzed here have been sequenced by the SeqCOVID consortium, while the remaining 208 have been generated by independent laboratories and downloaded from GISAID¹¹ (Supplementary Table 1). Spain displayed a particular viral population structure with a higher proportion of lineage A sequences compared to other European countries¹⁸ (Figure 1c). Strains from patients in Spain were more closely related with strains from cases sequenced in China and were the most abundant during the first weeks of the epidemic in Spain. They were replaced, later on, by lineage B strains (Extended Data Figure 1), which differ by at least 6-7 substitutions from lineage A and that dominated the beginning of the pandemic in most European countries, in contrast to the patterns seen in Spain. In addition, we observed a heterogeneous distribution of the SARS-CoV-2 genetic diversity within Spain, both at the regional and local levels. For example, our analysis shows that viral diversity was higher in some urban areas, and it declined with geographic distance from the city centers, as observed in Valencia (Supplementary Note).

Phylogenomic analyses suggest the existence of multiple independent entries of the virus into Spain, similar to what was seen for other countries^{19,20}. To identify possible introductions, we inspected the placement of Spanish viral samples in a global phylogeny constructed with more than 30,000 sequences (Figure 1d). Given the low genetic diversity of the virus, particularly at the beginning of the epidemic, we found many instances in which a Spanish sample was genetically identical to other variants circulating in the rest of the world. According to their phylogenetic placement, three different possibilities were considered for the phylogenetic position of Spanish sequences. A sequence was included in a 'candidate transmission cluster' when it was found in a monophyletic clade with other Spanish sequences; it was included in a 'zero distance' group when it grouped with other genetically identical Spanish sequences but also with other foreign sequences; and it was denoted as 'unique' when no matching sequence in the Spanish dataset was identified and the sequence differed by more than one single nucleotide polymorphism (SNP) from other Spanish sequences (Supplementary Figure 1a; detailed definitions of the groups are in Methods and Extended Data Figure 2). We detected 224 'candidate transmission clusters', comprising 827 sequences (~40% of the Spanish samples); 30 'zero-distance clusters', comprising 831 sequences, and 513 'unique' sequences (Supplementary Figure 2). Next, we determined how many unique cases and clusters were compatible with an introduction before the general lockdown. We detected that 191 groups (165 'candidate transmission clusters' plus 26 'zero distance clusters') and 328 unique sequences met this criterion, representing at least 519 independent introductions (distribution of dates in Figure 1e, distribution of 'unique' sequences across regions in Supplementary Figure 1b). This is probably an underestimate of the total number of entries because the number of sequences analyzed is a small subset of the total notified cases (Figure 1a). Phylogenetic analysis

suggests that the most likely introductions of cases with a clear phylogenetic link (Methods) came from Italy, the Netherlands, England, and Austria (accounting for ~23%, ~20%, ~13% and 12% of the cases for which a likely country of origin can be inferred, respectively) (Figure 1f). The observation that more than half of the introduction events detected are unique sequences illustrates the disparate outcomes after an introduction, as some events resulted in large epidemiological clusters, and others disappeared leaving almost no trace. A clear example is the case of the first described death in Spain for which we have generated a partial viral sequence. The patient was infected in Nepal but there were no identifiable secondary cases in our dataset.

A few genetic variants dominated the first wave in Spain

To identify those introductions that resulted in sustained transmission and therefore, the ones that were epidemiologically successful in the long-term, we scanned the phylogeny for larger clades mainly composed by Spanish samples (Methods). We identified nine Spanish Epidemic Clades (SEC) distributed across the phylogeny, representing 46% of the total Spanish dataset analyzed (995 out of 2,170 samples) (Figure 2a, Extended Data Figure 3, Extended Data Figure 4, Supplementary Table 1, Supplementary Table 2). We first noticed that only two SECs encompassed 30% and 10% of all Spanish samples (SEC8 and SEC7, respectively). This implies that the introduction of these two specific genetic variants explains a high proportion of the entire epidemic for the first wave in the country. In fact, they were responsible for 44% of the ‘candidate transmission clusters’ identified before the lockdown (Figure 2b). We then estimated the time of introduction in Spain for the nine SECs using a Bayesian approach (Supplementary Table 2). As a conservative estimate we considered the time of introduction as any time between the age of the most recent common ancestor of the SEC and the date of the first Spanish sample (Figure 2c). Thus, we assume that the ancestor of the SEC was not necessarily in Spain.

Our analysis shows that the earlier the introduction, the larger the size of the SEC (Supplementary Figure 3). The larger clades, SEC7 and SEC8, were the first successful genetic variants introduced into Spain during late January - February 2020 (Figure 2b). Both belong to lineage A (Pango nomenclature) and partially explain the particular population structure observed in Spain relative to other European countries (Figure 1c). In addition, compared with other SECs, SEC7 and SEC8 were widely spread in the country, being present in at least 10 of the 17 administrative regions (Figure 2b), and having a mean pairwise geographic distance between samples of more than 300 km, regardless whether or not the Islas Canarias and Baleares are included (Extended Data 5). On the contrary, SECs that were introduced later were smaller and showed a narrower geographic spread (between 0 - 58 km, ANOVA adjusted p-value $\ll 0.01$, Supplementary Note).

Superspreading events and mobility led to success of SEC8

Why some genetic variants succeed over others cannot be answered from genomic sequence data alone. We must also consider the epidemiological dynamics in the country. There are data supporting a role for the spike protein mutation 614G in epidemiological success. However, SEC7 and SEC8 do not harbor the mutation, explaining why 614G was less

frequent in Spain during the first weeks of the epidemic than in other countries (Extended Data 6). In addition, analysis of signature positions for both SECs did not lead to any likely genomic determinant of epidemiological success (Supplementary Table 3). Unfortunately, we had no access to linked epidemiological data for the complete dataset. However, we had access to detailed information from two superspreading events linked to SEC8. Based on the phylogenetic analysis and the linked epidemiological data, we are able to shed light on the early success of SEC8, the dynamics of which can be explained in three stages.

In the first stage, SEC8 was introduced at least twice from Italy to the city of Valencia (Figure 3a). There is epidemiological evidence that the individual in both cases became infected in Italy, as they attended the Atalanta-Valencia Champions League football match on 19th February 2020, and that one of them initiated a transmission chain of at least 24 cases according to Public Health, upon returning to Valencia a few days later. 12 of these 24 cases were sequenced (Figure 3a, highlighted in orange). This epidemiological link strongly suggests that the SEC8 genetic variant was imported from Italy. This introduction occurred in agreement with the estimated time of entry of SEC8 into Spain (Supplementary Table 2). NextStrain tracking tools for viral spatial spread suggest additional SEC8-related early seedings in Madrid, País Vasco, Andalucía, and La Rioja regions (Supplementary Data 2) which might have involved other countries, not exclusively Italy. Given the lack of genetic differentiation of the virus and scarce epidemiological information there is no certainty on whether these infections resulted from independent introductions from abroad or from internal migrations of infected persons, although the simultaneous detection in different regions favors the first option. Most of these multiple introductions occurred during the second half of February 2020, a period in which more than 11,000 daily entries of travelers from Italy were recorded.

In a second stage, SEC8 was fueled by superspreading events (Supplementary Data 2). Based on the topology of the phylogenetic tree (Figure 2a), there were multiple clades within SEC8 involving a large number of very closely related sequences (1-3 SNPs) (Figure 3a). Of special relevance was a funeral on 23rd February 2020, with attendees from the País Vasco and La Rioja regions (Public Health officers estimated 800 attendees, resulting in 36 confirmed symptomatic cases) from which 25 samples were successfully sequenced (Figure 3a, highlighted in purple). Importantly, although they did not differ by more than two SNPs, these sequences are spread across the SEC8 phylogeny, suggesting the existence of many more non-sampled secondary cases across the country (Figure 3a). In a third stage, SEC8, after reaching high frequencies locally, was redistributed across the country and in less than two weeks it reached a prevalence of 60% among the sequenced genomes (Figure 3b), being present in almost every region analyzed. All these stages occurred between the first known diagnosed SEC8 case on 25th February 2020 (Supplementary Table 2) and before the lockdown on 14th March 2020, highlighting the need for very early containment measures to stop the spread of SARS-CoV-2.

Effect of lockdown on the major clades

In the second half of March 2020, Spain imposed a strict lockdown on non-essential services and movements. Consistently, the number of cases for all SECs dropped quickly after the

lockdown (Extended Data Figure 7). A Bayesian birth-death skyline analysis allowed us to evaluate the impact of the lockdown on the effective reproductive number (R_e) of the most successful SECs. The analyses of SEC7 (Extended Data Figure 8) and SEC8 (Figure 3c) resulted in similar estimates for R_e before the lockdown (2.10 with 95% highest posterior density, HPD: 1.67-2.62 and 3.14 HPD: 2.71-3.57, respectively) similar to the R_e estimated early in the epidemic for SARS-CoV-2^{21,22}. After the lockdown there was a substantial decrease to less than 0.5 in both cases (0.27 95% HPD: 0.06-0.47; 0.23 HPD: 0.15-0.32, respectively). The model also estimated that the date with highest support for a change in R_e roughly coincides with the start of the lockdown in Spain on 14th March 2020 (20th March HPD: 15-25th March; 9th March HPD: 8-10th March, respectively). In addition, we calculated the doubling time for both SECs²³. Before the corresponding date of change for R_e , the doubling time for SEC7 was estimated at 6.3 days (95% HPD: 4.3-10.2 days) and that for SEC8 at 3.3 days (95% HPD: 2.7 - 4.1 days). R_e values after those dates had a posterior distribution that did not include 1.0 for both SECs (Supplementary Note), a result that supports the reduction in the rate of increase of confirmed cases and that is in agreement with estimates from epidemiological models and data^{21,22}.

In addition, all the viral variants not included in the SECs, mostly harboring the 614G mutation, displayed a similar decrease in the number of cases after the lockdown compared with the most successful SECs (Extended Data Figure 9a). The impact of the measures implemented in the R_e was also evaluated in two representative Pango lineages carrying the 614G mutation, and a substantial decrease in R_e after the lockdown was observed, from an R_e greater than 1.5 to an R_e of ~0.25, similar to the results obtained for SEC7 and SEC8 (Extended Data 9b).

Discussion

Our analyses have revealed more than 500 independent introductions of SARS-CoV-2 into Spain between late January, coinciding with the first reported cases in our country^{2,24}, and mid-April 2020. The earliest entries corresponded to lineage A, matching the virus diversity profile reported for the country. This lineage was common in Asia but rare in the rest of Europe²⁵. We observed that two genetic variants (SEC7 and SEC8) of this lineage dominated the first stages of the epidemic wave in Spain, contrary to what was observed in other European countries. In fact, most cases described in Europe at the beginning of the pandemic were lineage B, which makes the situation in Spain more unique. This highlights the importance of epidemiological data, from which we know that SEC8 was introduced at least from Italy despite not being the dominant lineage in the country at that time and illustrating the role of founder effects early in the pandemic^{18,26,27}.

Reasons for why some variants dominate over others can be related to viral genetics, to founder events associated to particular variants, and to the implementation of different public health measures over time, not necessarily in an exclusive manner. The variant distribution could also be partly explained by sampling bias. No mutation likely associated with epidemiological success has been identified in our analyses of SEC7 and SEC8 (Supplementary Table 3). In fact, neither SECs carry the 614G mutation in the spike protein, contrary to what is seen in most lineage B variants (Extended Data Figure 6). The mutation

614G has been associated with increased viral shedding compared to the ancestral 614D variant in laboratory conditions²⁸ and in transmission studies^{29,30}. Consistently, our analysis supports the observations³⁰ that 614G strains had higher associated viral loads measured as lower cycle threshold (Ct) values (Supplementary Figure 4). However, one study reports that its actual role in the epidemic is doubtful³¹, suggesting that its impact on epidemic transmission was minor, if any. In the case of Spain, 614G did not account for the initial success of the epidemic because SEC7 and, in particular, SEC8 were much more common than other genetic variants until the lockdown (10% and 30% of cases respectively). Notably, 614G strains were introduced and expanded later, and closer to the start of lockdown, than 614D (Extended Data Figure 9a, Extended Data Figure 6), explaining the particular lineage structure observed in Spain (Figure 1c). In contrast, founder events seem to have played an important role for the two major SECs. Our analysis shows that these two SECs were the first variants introduced in the country and, at least in the case of SEC8, were linked to very early superspreading events that contributed to their success. However, an early introduction of lineage A variants also occurred in other European countries, but they did not take hold and were displaced sooner by lineage B. Despite the early adoption of strong NPI measures, we hypothesize that epidemic control in the first wave in Spain was soon overwhelmed as compared to countries that controlled early outbreaks¹⁵. This was likely associated with a strict implementation of the case definition by the WHO, which allowed for a stealth dispersion of the first introductions. Spain implemented one of the strictest lockdowns in Europe, with a high compliance from the population as tracked by mobility data³². The efficacy of NPI measures was evident a few weeks later, and it was reflected in the almost complete elimination of SEC7, SEC8, and most variants by the end of the first wave (Extended Data Figure 7, Extended Data Figure 9a). However, we do observe a replacement of lineage A (SEC7 and SEC8) just after the start of the lockdown by B.1 variants harboring D614G (Extended Data Figure 9a). Contrary to that of lineage A, the spread of B.1 variants in Spain was represented by smaller SECs and more isolated cases. Likely these smaller clusters correspond to a new stage in the epidemic at the national level characterized by more limited mobility and social interactions.

This study has several limitations. Even though Spain is one of the countries with high contribution to public repositories, our dataset only represents a small subset of confirmed cases that occurred in the first COVID-19 wave (1% of cases). Moreover, sampling across the country was heterogeneous and the representation of each region in the dataset was not always proportional to the incidence during the studied period. Lack of genome data from countries with high disease burden, especially at the beginning of the pandemic, may have prevented a reliable identification of their likely sources based only on viral genome sequences. In addition, we did not have access to individual patient data for most cases. These caveats could have an impact in, for example, an exact quantification on the number of introductions, which will be always an estimate. However, our analysis already gives clues about the role of multiple introductions in the early days of the epidemic. Despite these limitations, we have been able to investigate some of the key cases and events that initiated the epidemic in Spain. This allowed us to understand the origin and early spread of SEC8, which would not have been possible based only on genome data. But we have also shown

that genetic data can be used to accurately estimate relevant epidemiological parameters, such as R_e and doubling times, even when the proportion of sampling is low.

We believe that our results allow us to draw lessons for the control of this, as well as future, pandemics. First, we have shown how specific variants can be used to track the effectiveness of public health control measures. In February 2020, the number of SEC8 cases was just a few dozen and yet it ended up accounting for 60% of the sequenced samples in the first weeks of March 2020. Second, the closure of borders to countries with high incidence is relevant to reduce simultaneous and multiple imports of the virus, but efficacy of these restrictions also depends on the internal incidence of the disease³³. The most successful SECs during the first wave were probably those that arrived early, multiple times, and to diverse locations. Thus, as suggested elsewhere³⁶, founder effects are important for the success of certain variants. Third, SEC7 and SEC8 spread across Spain in a matter of days. Controlling mobility is essential when the level of community transmission is high, as demonstrated by the significant decrease in R_e for these high-transmission genetic variants after the lockdown. As a comparison, before the lockdown, R_e values were 50% higher in Spain (3.3 for SEC8) than in Australia (1.63), and they underwent a reduction down to 7% of the original value (0.23) as a result of the containment measures, compared to a reduction to 30% (0.48) in Australia¹⁷. From a public health perspective, our results add to the evidence that the success of specific genetic variants, with no intrinsic biological difference, is fueled by superspreading events which rapidly increase the prevalence of the virus³⁴. Subsequently, coupled to the high mobility of our connected world, a variant may end up dominating the epidemic in a particular geographic location. This is what occurred with SEC8 and what at a local level has been described in Boston³⁵. In fact, we have recently described a new variant in Europe that was rapidly growing in several countries during the Summer of 2020, which is also linked to initial superspreading events³⁶. In contrast, new variants with different transmissibility and immunogenicity profiles started to merge at the end of 2020. Some of these variants, like B.1.1.7 (alpha) were able to replace existing variants in a matter of months. For the first wave in Spain, the conclusion is that early diagnosis and notification of cases would have helped to a timely implementation of effective contact tracing that, coupled with earlier mobility closures and maybe tighter border control, could have probably delayed by a few days the expansion of genetic variants, such SEC8, during the early stages of the epidemic. Whether this might have changed the global shape of the epidemic in the country or whether other genetic variants would have performed this role instead, leading to a similar outcome, cannot be ascertained. The comparison with other countries leads us to suspect that the difference would have been minimal.

Methods

SeqCOVID sampling and sequencing

RNA samples were received from different hospitals, and confirmed as SARS-Cov-2-positive by RT-PCR by Microbiological Services. Samples consisted of the remaining RNA extracts from naso- and oropharyngeal clinical specimens employed for diagnosis. The use of such samples has been approved by the ethics committee Comité Ético de Investigación

de Salud Pública y Centro Superior de Investigación en Salud Pública (CEI DGSP-CSISP) N° 20200414/05.

In general, we applied the following criteria for selecting the samples that underwent sequencing: i) only one sample per patient, ii) diagnosis PCR should have a cycle threshold (Ct) under 30, iii) prioritize samples from poorly sampled regions and hospitals, to maximize geographic diversity, iv) prioritize samples according to their diagnosis date, to maximize sampling of high incidence periods. These criteria were adopted weeks before the beginning of the project, after analyzing the firsts sets of sequences so, in the initial weeks, we did not pre-selected the samples for sequencing.

In the SeqCovid consortium webpage (<http://seqcovid.csic.es/>), the number of samples received, sequenced and uploaded to public repositories are shown and updated periodically.

RNA was retro-transcribed into cDNA and SARS-CoV-2 complete genome amplification was conducted in two multiplex PCR, accordingly to openly available protocol developed by the ARTIC network³⁸ using the V3 multiplex primers scheme³⁹. Two resulting amplicon pools were combined and used for library preparation. Genomic libraries were constructed with the Nextera DNA Flex Sample Preparation kit (Illumina Inc., San Diego, CA) according to the manufacturer's protocol, with 5 cycles for indexing PCR. Whole genome sequencing was carried out in the MiSeq platform (2×200 cycles paired-end run; Illumina).

The sequences obtained went through a bioinformatic pipeline based on IVAR⁴⁰, which is open source and can be accessed at <https://gitlab.com/fisabio-ngs/sars-cov2-mapping>. In short, the pipeline goes through the following steps: 1) Removal of the human reads with Kraken⁴¹; 2) filtering of the fastq files using fastp v 0.20.1⁴² (arguments: --cut tail, --cut-window-size, --cut-mean-quality, -max_len1,-max_len2); 3) mapping and variant calling using bwa and IVAR v 1.2 (variant calling cut-offs: minimum quality for SNP calling = 20, minimum frequency to call a SNP = 0.05, minimum depth for calling a SNP = 20, consensus construction cut-offs: minimum quality for consensus calling=20, minimum frequency to consider fixed a SNP=0.8, minimum position depth=30 (ambiguous base otherwise)); 4) quality control assessment with MultiQC⁴³.

Global alignment and phylogenetic reconstruction

To build the global alignment, we downloaded and concatenated all non-Spanish sequences present in GISAID⁴⁴ on 21st June 2020 that passed strict filtering criteria: i) sequences should have more than 29,000 bp length, ii) verified insertions/deletions, iii) less than 1% of Ns and less than 0.05% of unique amino acid mutations (compared with other sequences in GISAID).

Later, we added all Spanish sequences deposited in GISAID up to July 29th 2020. The final alignment constructed included 32,914 sequences. The accession numbers of the sequences used in this study can be found in Supplementary Table 1.

Sequences were aligned against the SARS-CoV-2 reference genome⁴⁵ using MAFFT⁴⁶. Specific positions that have been reported to be problematic for phylogenetic

reconstruction⁴⁷ were masked, following the procedure described by Rob Lanfear⁴⁸, using the `mask_alignment.sh` script.

Finally, a maximum-likelihood (ML) phylogeny was reconstructed using IQTREE⁴⁹ with the GTR model and based on the complete masked genome alignment. This phylogeny was rooted to the SARS-CoV-2 sequence obtained in Wuhan on 24/12/2019 (GISAID ID: EPI_ISL_402123).

Identification of introductions and transmission clusters

We identified transmission groups between Spanish sequences by inspecting the global phylogeny (32,914 leaves) and searching for Spanish sequences (or groups of) that were embedded within sequences with other geographic origins. Given the general low diversity among sequences, most phylogenetic nodes ended up being polytomic in the maximum-likelihood tree. Because of this, we defined three different transmission scenarios: i) strains that represent introductions in Spain but differ from those from other countries and form well defined transmission groups ('candidate transmission clusters'); ii) strains introduced into Spain that are equal to other Spanish sequences and that are also equal to sequences from other countries ('zero distance clusters'); and iii) Spanish sequences found within groups of sequences from other countries and which are not phylogenetically near any other Spanish sequences ('unique'). The 'candidate transmission clusters' were identified as monophyletic groups of sequences composed exclusively by Spanish sequences in the phylogeny. The 'zero distance clusters' were identified as Spanish sequences that share a common ancestor and that are at 0 SNP distance from each other. Finally, the 'unique' sequences were identified as those sequences which do not share their most recent ancestor with any other Spanish sequence. Next, we inferred how many of these transmission groups have a potential contagion date for their first case that predates the start of mobility restrictions, on 14th March 2020, by subtracting 14 days to the diagnosis date.

Finally, we wanted to investigate the international origin of these introductions. For each of the identified groups or 'unique' sequences with an inferred contagion date before 14th March 2020, we looked for the closest non-Spanish sequence in the phylogeny with a diagnosis date predating the first case of the transmission group. As the current consensus is that the pandemic began in Asia and later it moved to Europe, we considered only those sequences with an Asian or European origin as potential sources of introductions.

SEC alignment and phylogeny

Using the global phylogeny, we identified nodes which had at least 20 leaves and in which at least 50% of these correspond to Spanish sequences. Next, for each of these nodes or clades we reconstructed an alignment of the complete masked genomes including: a.) the sequences that belong to the identified clade; b.) 11 basal sequences from Wuhan acting as an 'anchor' for the phylogeny (Supplementary Table 1); c.) a subset of 51 representative sequences, each one from a different pangolin lineage, selected to maximize the global SARS-CoV-2 genetic diversity (Supplementary Table 1, downloaded from GISAID on 2020-07-20).

For each of these alignments we inferred a ML phylogeny, using IQTREE⁴⁹, with the model GTR, 1,000 fast-bootstrap replicates and rooted to the Wuhan sequence (EPI_ISL_402123).

Then, in the resulting phylogeny we identified less inclusive nodes embedded within the above identified clades and had a bootstrap support value > 80 . These clades were named as potential Spanish epidemic clades (SEC). The iTOL tool⁵⁰ was used for phylogenetic visualization.

SEC8 detailed analysis

To get more detail on SEC8 phylogenetic structure, and to evaluate if mobility restrictions were effective to hinder SEC8 transmission, we enriched the original SEC8 phylogenetic tree with all the isolates of this clade sampled from February to October 2020 by the SeqCOVID consortium (959 sequences in total). Later, epidemiological information was included and plotted in the tree using the iTOL tool⁵⁰.

SEC8 potential superspreading events were defined as groups of more than 10 sequences, having at least 1 SNP in common and having a within sequence median distance from 1 to 3 SNPs.

Population genetics and differentiation geography

Geographic distance between sequences were computed using the GPS coordinates of the patient residence city and applying the Vicenty (ellipsoid) method. Genetic diversity was calculated with two different methods: i) genetic distance between each pair of samples in number of substitutions (SNPs), and ii) number of base substitutions per site averaged over all sequence pairs in a group of sequences. Both values have been estimated using the MEGA software⁵¹, skipping one position when a gap is found in the two compared sequences. Demographic data for all Spanish regions and municipalities were downloaded from INE (<https://www.ine.es/>), and had been updated on 1st January, 2020.

The genetic diversity heatmap of the Comunidad Valenciana autonomous region was generated with QGIS v.3.14.16-Pi⁵², using the inverse distance weighting (IDW) algorithm to interpolate the mean genetic diversity of each municipality for which we had at least two sequences.

To compare the genetic and geographic distance distribution between the different SECs, we used a one-way ANOVA test, followed by multiple pairwise-comparisons of the between-groups mean with a Tukey HSD test.

Dating analyses

To estimate the most recent common ancestor (MRCA) of each of the nine SECs defined above, a multi-sequence alignment was performed including the 11 samples belonging to basal phylogenetic clades and the 51 representative sequences from different lineages (Supplementary Table 1). Before phylogenetic dating, root-to-tip regression of genetic divergence against sampling dates was performed to investigate the molecular clock signal of SECs using TempEst v 1.5.3⁵³. We implemented a coalescent Bayesian exponential growth model available in Beast 2.6⁵⁴ with the HKY+ Γ model of nucleotide substitution. Tree priors were defined as follows: for effective population size we used a lognormal distribution ($M=1$, $S=2$) and for growth rate a Laplace distribution ($M=0$, $S=100$). The

uncorrelated lognormal relaxed clock was selected as the best fitting clock model using Bayes Factor comparisons of strict and relaxed clocks based on path sampling/stepping stone analysis⁵⁵. Clock priors were defined as: *ucl.d.mean*: lognormal distribution with mean in real space = 1.4×10^{-3} subs/site/year and *ucl.d.stdev* = 5×10^{-2} . Parameters were estimated using Markov Chain Monte Carlo (MCMC) Bayesian inference, with 5×10^7 steps-long chains with exception of SEC7 and SEC8, for which longer chains were run (1×10^8), in all cases a total of 10^5 steps were sampled in the log files. For all analysis, three independent runs starting from different seeds were conducted in order to ensure convergence, then combined with LogCombiner v 2.6.3 after removing the initial 10% of the MCMC as burn-in. Adequate mixing of parameters and convergence among runs were assessed using Tracer v 1.7.1⁵⁶ by verifying that each parameter reached an effective sampling size (ESS) above 200 and that traces showed stationarity and good mixing. The final posterior distribution contained a total of 9,000 trees, annotated with Treeannotator v 2.6.3 and visualized in FigTree v 1.4.3⁵⁷

Phylodynamics analysis to estimate R_e

To estimate discrete changes in R_e through for the two largest epidemic clades SEC7, SEC8 and two Pango lineages harboring the 614G mutation (B.1, B.1.1). We used a Bayesian birth-death skyline model (BDSKY) with serial sampling⁵⁸ implemented in BEAST v 2.6⁵⁴. BDSKY uses an episodic, piecewise birth-death model in which the parameter is allowed to change at discrete points in time, with the magnitude and timing of changes estimated from the data. In our analysis, we set two intervals wherein R_e is constant and estimated the date with most evidence for a change in R_e . To this end, we set a uniform prior distribution. R_e was estimated before and after the changing time. Same parameters as above were used but fixing the clock rate and the recovery rate (become uninfected rate, $\delta = 36.5 \text{ years}^{-1}$) in accordance with consistent global estimates of an infectious period of 10 days⁵⁹. In order to avoid bias in the model parameters due to constant sampling proportion assumed by BDSKY models, this parameter was set to zero before the first sample date using TreeSlicer (<https://github.com/laduplessis/skylinetools/wiki>). For this analysis a 1×10^8 and 4×10^8 steps-long chains were used for SEC7/B.1/B.1.1 and SEC8 respectively. Results were inspected with Tracer (v 1.7.1)⁵⁶ by verifying that every parameter had effective sampling sizes above 200 and well mixing was obtained. Doubling time was calculated from the parameters estimated by BDSKY model in which growth rate(r) = $(R_e * \delta) - \delta$ and doubling time = $\ln(2) / r$.

Statistical analysis

All statistical analyses were carried out using the R statistical language⁶⁰. Packages *ape*⁶¹, *treeio*^{61,62}, *doParallel*⁶³ and *foreach*⁶⁴ were used for phylogenetic manipulation and analysis. We additionally used packages *geosphere*⁶⁵, *lwgeom*⁶⁶, *sp*⁶⁷, *sf*⁶⁸ and *rgeos*⁶⁹ to calculate the geographic distances between samples and the geographical representation in the data. The *ggplot2* R package⁷⁰ was extensively used for analysis and data plotting.

Epidemic wave definitions


There is not a formal (or even official) definition for “first” and “second” wave, and the valley between both. We therefore have used two lines of evidence to define the boundaries.

One is the official number of total cases diagnosed by PCR⁷¹ and the second is the end of the mobility restrictions. Based on these facts, we tentatively identify the following dates for the different waves

First wave: February 2020 - 14 May 2020 (from the first case reported to the end of the national lockdown and start of lifting measures).


Second wave: July 2020 - First week of December 2020 (from the first large outbreaks reported after the first wave, which were caused and led to the expansion of the 20E/EU1 variant across the country to the new increase of cases in December).

Extended Data




Extended Data Fig. 1. Abundance of the different Pango lineages in the dataset
In the x-axis, the epidemiological week as plotted in Microreact.


Candidate transmission cluster



Zero distance cluster




Unique




Extended Data Fig. 2. Examples of the different groups of sequences identified.

‘Candidate transmission clusters’ are groups of Spanish sequences that form a clade. ‘Zero distance clusters’ are groups of Spanish sequences that are at zero distance from each other.


Finally, the ‘unique’ sequences are Spanish sequences that are more than 1 SNP away from any other Spanish sequence and that do not share a most recent common ancestor (MRCA) node with other Spanish sequences



Extended Data Fig. 3. Number of international and Spanish sequences in each SEC.




Extended Data Fig. 4. Phylogenetic location of each SEC in the global SARS-CoV-2 phylogeny. Sequences from Spain are colored according to their SEC color (as indicated in Figure 2a legend) while international sequences remain in black color.




Extended Data Fig. 5. Distribution of genetic (salmon) versus geographic (grey) distances within each pair of samples belonging to the same SEC.

For each SEC we had the following comparisons (data points): SEC1 (N=120), SEC2 (N=190), SEC3 (N=91), SEC4 (N=325), SEC5 (N=378), SEC6 (N=990), SEC7 (N=14,028), SEC8 (N=178,503) and SEC9 (N=231). The lower whisker, higher whisker, center and bounds of each box plot refers to quartile 1 + 1.5 interquartile range, quartile 3 + 1.5 interquartile range, mean, first and third quartiles of the data. Individual points are outliers (values lower than quartile 1–1.5 interquartile range and higher than quartile 3 + 1.5 interquartile range).




Extended Data Fig. 6. Distribution of sequences harbouring the 614G mutation (blue) versus the 614D mutation (salmon, wild-type) in the S gene for the spanish sequences in our dataset.

In the left panel, a histogram of samples sorted by date of sequencing. At right, frequency of both mutations in the sequenced samples by date. The national lockdown event is marked by a purple vertical line. At the bottom, 'candidate transmission clusters' by date and size, coloured according to the allele found at the 614 position of the S gene.



Extended Data Fig. 7. Cases sequenced during the period that includes the first wave until the end of the lockdown (14th May, 2020).


Lines represent the number of cases belonging to different Spanish Epidemic Clades (SECs).



Extended Data Fig. 8. Phylodynamic estimates of the effective reproductive number (R_e) of Spanish SEC7.

A birth–death skyline (BDSKY) model was implemented in Beast v.2, allowing for piecewise changes in R_e , with the time and magnitude estimated from the data. The X axis represents time, starting with the MRCA of all sampled diversity within SEC7 and ending with the date of the most recently sequenced genome from 15th May. The blue dotted line indicates the posterior value of the timing of a most significant decrease in R_e , around 20th March 2020 [95% HPD: 15–25th March]. The Y axis represents R_e , and the violin plots show the posterior probability distribution for this parameter before and after the change

time in R_e ; with a mean of 2.10 [95% HPD: 1.67–2.62] and 0.27 [95% HPD:0.06–0.47] before and after this time, respectively. The phylogenetic tree in the background is the maximum clade credibility tree from the BDSKY analysis, with the tips colored according to whether they were sampled before or after 20th March. The lower whisker, higher whisker, center and bounds of each box plot refers to quartile 1–1.5 interquartile range, quartile 3 + 1.5 interquartile range, mean, first and third quartiles of the data. Individual points are outliers (values lower than quartile 1–1.5 interquartile range and higher than quartile 3 + 1.5 interquartile range). Boxplot was constructed with all the Spanish sequences in SEC7 (N=182).



Extended Data Fig. 9. Comparison between strains carrying 614D and 614G mutations.
a. Number of sequences belonging to SEC7, SEC8 (614D) and those having the 614G allele. **b.** Phylodynamic estimates of the effective reproductive number (Re) of clades harbouring 614D mutation (SEC7 and SEC8) and Pango lineages with 614G mutation (B.1 and B.1.1). A birth–death skyline (BDSKY) model was implemented in Beast v.2, allowing for piecewise changes in Re , with the time and magnitude estimated from the data. The violin plots show the posterior probability distribution (HPD) interval for Re parameter before ($Re1$) and after ($Re2$) the changing time estimates (dotted line). For SEC7, $Re1$:

2.10 [95% HPD: 1.67–2.62] and Re2: 0.27 [95% HPD:0.06–0.47]; changing time 20th March 2020 [95% HPD: 15–25th March]. For SEC8, Re1: 3.14 [95% HPD: 2.71-3.57] and Re2: 0.23 [95% HPD: 0.15-0.32]; changing time 9th March 2020 [95% HPD: 8–10th March]. For B.1, Re1: 1.86 [1.6-2.16] and Re2: 0.26 [0.14-0.41]; changing time 23rd March 2020 [95% HPD: 21–25th March]. For B.1.1, Re1: 1.62 [1.44-1.80] and Re2: 0.15 [0.05-0.29]; changing time 10th April 2020 [95% HPD: 9–12th April]. The lower whisker, higher whisker, center and bounds of each box plot refers to quartile 1–1.5 interquartile range, quartile 3 + 1.5 interquartile range, mean, first and third quartiles of the data. Individual points are outliers (values lower than quartile 1–1.5 interquartile range and higher than quartile 3 + 1.5 interquartile range). Boxplots were constructed with all the Spanish sequences in SEC7 (N=182), SEC8 (N=636), B.1 (N=191) and B.1.1 (N=223).

Extended Data Fig. 10.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Mariana G. López^{#1}, Álvaro Chiner-Oms^{#1}, Darío García de Viedma^{2,3,4}, Paula Ruiz-Rodriguez⁵, María Alma Bracho^{6,7}, Irving Cancino-Muñoz¹, Giuseppe D'Auria^{7,8}, Griselda de Marco⁸, Neris García-González⁶, Galo Adrian Goig⁹, Inmaculada Gómez-Navarro¹, Santiago Jiménez-Serrano¹, Lúcia Martínez-Priego⁸, Paula Ruiz-Hueso⁸, Lidia Ruiz-Roldán⁶, Manuela Torres-Puente¹, Juan Alberola^{10,11,12}, Eliseo Albert¹³, Maitane Aranzamendi Zaldumbide^{14,15}, María Pilar Bea-Escudero¹⁶, Jose Antonio Boga^{17,18}, Antoni E. Bordoy¹⁹, Andrés Canut-Blasco²⁰, Ana Carvajal²¹, Gustavo Cilla Eguiluz²², María Luz Cordón Rodríguez²⁰, José J. Costa-Alcalde²³, María de Toro¹⁶, Inmaculada de Toro Peinado²⁴, Jose Luis del Pozo²⁵, Sebastián Duchêne²⁶, Jovita Fernández-Pinero²⁷, Begoña Fuster Escrivá^{12,28}, Concepción Gimeno Cardona²⁸, Verónica González Galán²⁹, Nieves Gonzalo Jiménez³⁰, Silvia Hernáez Crespo²⁰, Marta Herranz^{2,3,4}, José Antonio Lepe²⁹, Carla López-Causapé³¹, José Luis López-Hontangas³², Vicente Martín^{7,33}, Elisa Martró^{7,19}, Ana Milagro Beamonte³⁴, Milagrosa Montes Ros²², Rosario Moreno-Muñoz³⁵, David Navarro^{13,12}, José María Navarro-Mari^{36,37}, Anna Not¹⁹, Antonio Oliver^{31,38}, Begoña Palop-Borrás²⁴, Mónica Parra Grande³⁹, Irene Pedrosa-Corral^{36,37}, María Carmen Pérez González⁴⁰, Laura Pérez-Lago^{2,3}, Mercedes Pérez-Ruiz²⁴, Luis Piñeiro Vázquez²², Nuria Rabella^{41,42,43}, Antonio Rezusta^{34,44,45}, Lorena Robles Fonseca⁴⁶, Ángel Rodríguez-Villodres²⁹, Sara Sanbonmatsu-Gámez^{36,37}, Jon Sicilia^{2,3}, Alex Soriano⁴⁷, María Dolores Tirado Balaguer³⁵, Ignacio Torres¹³, Alexander Trstancho^{34,44}, José María Marimón²², SeqCOVID-Spain consortium

List of the SeqCOVID-SPAIN consortium members

Álvaro Chiner-Oms¹, Irving Cancino-Muñoz¹, Mariana G. López¹, Manoli Torres-Puente¹, Inmaculada Gómez-Navarro¹, Santiago Jiménez-Serrano¹, Jordi Pérez-Tur¹, Darío García de Viedma^{2,3,4}, Laura Pérez-Lago^{2,3}, Marta

Herranz^{2,3,4}, Jon Sicilia^{2,3}, Pilar Catalán-Alonso^{2,3,4}, Julia Suárez González³, Patricia Muñoz^{2,3,4}, Mireia Coscolla⁵, Paula Ruiz-Rodríguez⁵, Fernando González-Candelas^{6,7}, Iñaki Comas^{1,7}, Lidia Ruiz-Roldán⁶, María Alma Bracho^{6,7}, Neris García-González⁶, Llúcia Martínez Priego⁸, Inmaculada Galán-Vendrell⁸, Paula Ruiz-Hueso⁸, Griselda De Marco⁸, Loreto Ferrús-Abad Ma⁸, Sandra CarbóRamírez⁸, Giuseppe D'Auria^{7,8}, Galo Adrian Goig⁹, Juan Alberola^{10,11,12}, Jose Miguel Nogueira^{10,11,12}, Juan José Camarena^{10,11,12}, David Navarro^{12,13}, Eliseo Albert¹³, Ignacio Torres¹³, Maitane Aranzamendi Zaldumbide^{14,15}, Óscar Martínez Expósito^{14,15}, Nerea Antona Urieta^{14,15}, María de Toro¹⁶, María Pilar BeaEscudero¹⁶, Jose Antonio Boga^{17,18}, Cristian Castelló-Abietar^{17,18}, Susana Rojo-Alba^{17,18}, Marta Elena Álvarez-Argüelles^{17,18}, Santiago Melón^{17,18}, Elisa Martró^{7,19}, Antoni E. Bordoy¹⁹, Anna Not¹⁹, Adrián Antuori¹⁹, Anabel Fernández-Navarro¹⁹, Andrés Canut-Blasco²⁰, Silvia Hernáez Crespo²⁰, Maria Luz Cordón Rodríguez²⁰, Maria Concepción Lecaroz Agara²⁰, Carmen Gómez-González²⁰, Amaia AguirreQuiñonero²⁰, José Israel López-Mirones²⁰, Marina Fernández-Torres²⁰, Maria Rosario Almela-Ferrer²⁰, Ana Carvajal²¹, Juan Miguel Fregeneda-Grandes²¹, Héctor Argüello²¹, Gustavo Cilla Eguiluz²², Milagrosa Montes Ros²², Luis Piñeiro Vázquez²², Ane Sorarrain²², José María Marimón²², José J. Costa-Alcalde²³, Rocío Trastoy²³, Gema Barbeito Castiñeiras²³, Amparo Coira²³, María Luisa Pérez del Molino²³, Antonio Aguilera²³, Begoña Palop-Borrás²⁴, Inmaculada de Toro Peinado²⁴, Maria Concepción Mediavilla Gradolph²⁴, Mercedes Pérez-Ruiz²⁴, Mirian Fernández-Alonso²⁵, Jose Luis del Pozo²⁵, Oscar GonzálezRecio²⁷, Mónica Gutiérrez-Rivas²⁷, Jovita Fernández-Pinero²⁷, Miguel Ángel Jiménez Clavero²⁷, Begoña Fuster Escrivá^{12,28}, Concepción Gimeno Cardona²⁸, María Dolores Ocete Mochón²⁸, Rafael Medina-Gonzalez²⁸, José Antonio Lepe²⁹, Verónica González Galán²⁹, Ángel Rodríguez-Villodres²⁹, Nieves Gonzalo Jiménez³⁰, Jordi Reina³¹, Carla López-Causapé³¹, Maria Dolores Gómez-Ruiz³², Eva M. Gonzalez-Barbera³², José Luis López-Hontangas³², Vicente Martín^{7,33}, Antonio J. Molina³³, Tania Fernandez-Villa³³, Ana Milagro Beamonte³⁴, Nieves Felisa Martínez-Cameo³⁴, Yolanda GraciaGrataloup³⁴, Rosario Moreno-Muñoz³⁵, Maria Dolores Tirado Balaguer³⁵, José María Navarro-Mari^{36,37}, Irene Pedrosa-Corral^{36,37}, Sara Sanbonmatsu-Gámez^{36,37}, Antonio Oliver^{31,38}, Mónica Parra Grande³⁹, Bárbara Gómez Alonso³⁹, Francisco José Arjona Zaragoza³⁹, Maria Carmen Pérez González⁴⁰, Francisco Javier Chamizo López⁴⁰, Ana Bordes-Benítez⁴⁰, Núria Rabella^{41,42,43}, Ferran Navarro^{41,42,43}, Elisenda Miró^{41,42}, Antonio Rezusta^{34,44,45}, Alexander Tristancho^{34,44}, Encarnación Simarro Córdoba⁴⁶, Julia Lozano-Serra⁴⁶, Lorena Robles Fonseca⁴⁶, Álex Soriano⁴⁷, Francisco Javier Roig Sena⁴⁸, Hermelinda Vanaclocha Luna⁴⁸, Isabel Sanmartín⁴⁹, Daniel García-Souto^{50,51,52}, Ana Pequeño-Valtierra⁵⁰, Jose M. C. Tubio^{50,51}, Javier Temes^{50,51}, Jorge Rodríguez-Castro⁵⁰, Martín Santamarina García⁵⁰, Manuel RodríguezIglesias^{53,54,55}, Fátima Galán-Sanchez^{53,54,55}, Salud Rodríguez-Pallares^{53,54}, José Manuel AzconaGutiérrez⁵⁶, Miriam Blasco-Alberdi⁵⁶, Alfredo Mayor^{7,57,58}, Alberto L. García-Basteiro^{57,58},

Gemma Moncunill⁵⁷, Carlota Dobaño⁵⁷, Pau Cisteró⁵⁷, Oriol Mitjà^{59,60}, Camila González-Beiras⁵⁹, Martí Vall-Mayans⁵⁹, Marc Corbacho-Monné⁵⁹, Andrea Alemany⁵⁹, Cristina Muñoz-Cuevas^{61,62}, Guadalupe Rodríguez-Rodríguez^{61,62}, Rafael Benito^{45,63}, Sonia Algarate⁶³, Jessica Bueno⁶³, Andrea VergaraGómez⁶⁴, Miguel J. Martínez^{57,65,66}, Jordi Vila^{57,65}, Elisa Rubio^{57,65}, Aida Peiró-Mestres^{57,65}, Jessica Navero-Castillejos^{57,65}, David Posada^{67,68,69}, Diana Valverde^{67,68,69}, Nuria Estévez⁶⁷, Iria FernándezSilva^{67,68}, Loretta de Chiara^{67,68}, Pilar Gallego-García⁶⁷, Nair Varela⁶⁷, Ulises Gómez-Pinedo⁷⁰, Mónica Gozalo-Margüello⁷¹, Maria Eliecer Cano García⁷¹, José Manuel Méndez-Legaza⁷¹, Jesus RodríguezLozano⁷¹, María Siller⁷¹, Daniel Pablo-Marcos⁷¹, Maria Montserrat Ruiz-García^{30,72}, Antonio Galiana⁷³, Judith Sánchez-Almendro⁷³, Maria Isabel Gascón Ros⁷⁴, Cristina Juana Torregrosa-Hetland⁷⁴, Eva María Pastor Boix⁷⁴, Paloma Cascales Ramos⁷⁴, Pedro Luis Garcinuño Enríquez⁷⁴, Salvador Raga Borja⁷⁴, Julia González Cantó⁷⁵, Olalla Martínez Macías⁷⁵, Adolfo de Salazar⁷⁶, Laura Viñuela González⁷⁶, Natalia Chueca⁷⁶, Federico García⁷⁶, Cristina Gómez-Camarasa⁷⁶, Amparo Farga Martí⁷⁷, Rocío Falcón⁷⁷, Victoria Domínguez-Márquez⁷⁷, Anna M. Planas⁷⁸, Israel Fernández-Cádenas⁷⁹, María Ángeles Marcos⁸⁰, Carmen Ezpeleta^{81,82}, Ana Navascués^{81,82}, Ana Miqueleiz Zapatero⁸¹, Manuel Segovia^{83,84}, Antonio Moreno-Docón^{83,84}, Esther Viedma⁸⁵, Raúl Recio Martínez⁸⁵, Irene Muñoz-Gallego⁸⁵, Sara Gonzalez-Bodi⁸⁵, Maria Dolores Folgueira⁸⁵, Jesús Mingorance⁸⁶, Elias Dahdouh⁸⁶, Fernando Lázaro-Perona⁸⁶, María Rodríguez-Tejedor⁸⁶, María Pilar Romero-Gómez⁸⁶, Julio García-Rodríguez⁸⁶, Juan Carlos Galán⁸⁷, Mario Rodríguez-Dominguez^{7,87,88}, Laura Martínez-García^{7,87,88}, Melanie Abreu Di Berardino^{87,88}, Manuel Ponce-Alonso^{87,88,89}, Jose Maria González-Alba^{87,88}, Ivan Sanz-Muñoz⁹⁰, Diana Pérez San José⁹⁰, Maria Gil Fortuño⁹¹, Juan B. Bellido-Blasco⁹¹, Alberto Yagüe Muñoz⁹¹, Noelia Henández Pérez⁹¹, Helena Buj Jordá⁹¹, Óscar Pérez Olaso⁹¹, Alejandro González Praetorius⁹², Nora Mariela Martínez Ramírez⁹², Aida Ramírez Marinero⁹³, Eduardo Padilla León⁹³, Alba Vilas Basil⁹³, Mireia Canal Aranda⁹³, Albert Bernet Sánchez⁹⁴, Alba Bellés Bellés⁹⁴, Eric López González⁹⁴, Iván Prats Sánchez⁹⁴, Mercè García-González⁹⁴, Miguel José Martínez-Lirola⁹⁵, Manuel Ángel Rodríguez Maresca⁹⁵, Maria Teresa Cabezas Fernández⁹⁵, María Eugenia Carrillo Gil⁹⁵, Maria Paz Ventero Martín⁹⁶, Carmen Molina Pardines⁹⁶, Nieves Orta Mira⁹⁷, María Navarro Cots⁹⁷, Inmaculada Vidal Catalá⁹⁷, Isabel García Nava⁹⁷, Soledad Illescas FernándezBermejo^{98,99}, José Martínez-Alarcón^{98,99}, Marta Torres-Narbona⁹⁸, Cristina Colmenarejo⁹⁸, Lidia GarcíaAgudo⁹⁸, Jorge A. Pérez García⁹⁸, Martín Yago López¹⁰⁰, María Ángeles Goberna Bravo¹⁰⁰, Victoria Simón García¹⁰¹, Gonzalo Llop Furquet¹⁰¹, Agustín Iranzo Tatay¹⁰¹, Sandra Moreno-Marro¹⁰¹, Noelia Lozano Rodríguez¹⁰¹, Amparo Broseta Tamarit¹⁰², Juan José Badiola Díez¹⁰³, Amparo MartínezRamírez¹⁰⁴, Ana Dopazo¹⁰⁵, Sergio Callejas¹⁰⁵, Alberto Benguría¹⁰⁵, Begoña Aguado¹⁰⁶, Antonio Alcamí¹⁰⁶, Marta Bermejo Bermejo¹⁰⁷, Ricardo Ramos-Ruiz¹⁰⁸, Víctor Manuel Fernández Soria¹⁰⁸, Fernando Simón Soria¹⁰⁹, Mercedes Roig Cardells¹¹⁰

- ⁴⁸Servicio de Vigilancia y Control Epidemiológico. Dirección General de Salud Pública y Adicciones. Conselleria de Sanitat Universal i Salut Pública. Generalitat Valenciana. Valencia, Spain**
- ⁴⁹Real Jardín Botánico, Consejo Superior de Investigaciones Científicas**
- ⁵⁰Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain**
- ⁵¹Department of Zoology, Genetics and Physical Anthropology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain**
- ⁵²Cancer Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Cambridge CB1 8PS, UK**
- ⁵³Servicio de Microbiología, H.U. Puerta del Mar, Cádiz, Spain**
- ⁵⁴INIBICA, Instituto de Investigación Biomédica de Cádiz, Cádiz, Spain**
- ⁵⁵Departamento de Biomedicina, Biotecnología y Salud Pública. Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain**
- ⁵⁶Laboratorio de Microbiología. Hospital San Pedro, Logroño, Spain**
- ⁵⁷ISGlobal, Barcelona Institute for Global Health, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain**
- ⁵⁸Centro de Investigaçao em Saude de Manhiça (CISM), Maputo, Mozambique**
- ⁵⁹Fight AIDS and Infectious Diseases Foundation, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, 08916 Badalona, Barcelona, Spain**
- ⁶⁰Lihir Medical Centre-InternationalSOS, Lihir Island, Papua New Guinea**
- ⁶¹Servicio de Microbiología Clínica. Hospital San Pedro de Alcántara, Cáceres, Spain**
- ⁶²Servicio Extremeño de Salud, Spain**
- ⁶³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain**
- ⁶⁴Servicio de Microbiología & CORE de Biología Molecular, CDB, Hospital Clínic, Barcelona, Spain**
- ⁶⁵Department of Microbiology - CDB, Hospital Clínic de Barcelona**
- ⁶⁶University of Barcelona, Barcelona, Spain**
- ⁶⁷CINBIO, Universidade de Vigo, Vigo, Spain**
- ⁶⁸Department of Biochemistry, Genetics, and Immunology, Universidade de Vigo, Vigo, Spain**
- ⁶⁹Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Spain**
- ⁷⁰IdiSSC/Hospital Clínico San Carlos, Madrid, Spain**

- ⁷¹ Hospital Marqués de Valdecilla - IDIVAL, Santander, Spain**
- ⁷² Departamento de Producción Vegetal y Microbiología. Universidad Miguel Hernández. Elche**
- ⁷³ Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana: Elche, Alicante, ES, (Hospital General Universitario de Elche, Microbiología)**
- ⁷⁴ Laboratorio de Microbiología. Hospital General Universitario de Elda. Elda, Alicante, Spain**
- ⁷⁵ Laboratorio Biología Molecular, Área de Diagnóstico Biológico, Hospital Universitario La Ribera, Alzira, Valencia, Spain**
- ⁷⁶ Hospital Universitario San Cecilio, Granada, Spain**
- ⁷⁷ Servicio de Microbiología, Hospital Arnau de Vilanova, Valencia, Spain**
- ⁷⁸ Biomedical Research Institute of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain**
- ⁷⁹ Sant Pau Hospital Research Institute, Barcelona, Spain**
- ⁸⁰ Microbiology Department, Hospital Clinic I Provincial de Barcelona. Institut of Global Health of Barcelona (ISGlobal), Barcelona, Spain**
- ⁸¹ Servicio de Microbiología Clínica, Complejo Hospitalario de Navarra (Pamplona, Navarra)**
- ⁸² Instituto de Investigación Sanitaria de Navarra (IdiSNA)**
- ⁸³ Servicio de Microbiología, Hospital Clínico Universitario Virgen de la Arrixaca, Spain**
- ⁸⁴ Departamento de Genética y Microbiología, Universidad de Murcia, Carretera Madrid-Cartagena sn,30120-El Palmar, Murcia, Spain**
- ⁸⁵ Hospital Universitario 12 de Octubre, Madrid, Spain**
- ⁸⁶ Hospital Universitario La Paz, IdiPAZ, Madrid, Spain**
- ⁸⁷ Servicio de Microbiología. Hospital Universitario Ramón y Cajal, Madrid, Spain**
- ⁸⁸ Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)**
- ⁸⁹ Red Española de Investigación en Patología Infecciosa (REIPI)**
- ⁹⁰ Centro Nacional de Gripe, Valladolid, Spain**
- ⁹¹ Hospital Universitari de La Plana, Vila-Real, Spain**
- ⁹² Hospital Universitario de Guadalajara, Guadalajara, Spain**
- ⁹³ Laboratori de Referència de Catalunya, Spain**
- ⁹⁴ Hospital Universitari Arnau de Vilanova de Lleida, Spain**

- ⁹⁵Complejo Hospitalario Universitario Torrecárdenas, Almería, Spain
- ⁹⁶Servicio de Microbiología. Hospital General Universitario de Alicante. Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL). Alicante, Spain
- ⁹⁷Hospital Francisc de Borja, Sección Microbiología, Spain
- ⁹⁸Hospital General Universitario de Ciudad Real, Spain
- ⁹⁹Facultad de Medicina de Ciudad Real. UCLM
- ¹⁰⁰Hospital General de Requena, Spain
- ¹⁰¹Laboratorio de Biología Molecular. Servicio de Análisis Clínicos y Microbiología. Hospital de Sagunto
- ¹⁰²Synlab - Hospital de Manises, Spain
- ¹⁰³Centro de Encefalopatías y Enfermedades Transmisibles Emergentes, Facultad de Veterinaria, Universidad de Zaragoza, Zaragoza, Spain
- ¹⁰⁴Universitat de València, Servei Cental de Suport a la Investigació Experimental (SCSIE), Sección de Genómica, València, Spain
- ¹⁰⁵Centro Nacional de Investigaciones Cardiovasculares (CNIC)
- ¹⁰⁶Centro de Biología Molecular Severo Ochoa (CBMSO) (CSIC-UAM), Nicolás Cabrera 1, Cantoblanco, 28049 Madrid, Spain
- ¹⁰⁷Unidad de Vigilancia de Salud y Medicina del Trabajo CSIC. Serrano 113p, 28006 Madrid. Spain
- ¹⁰⁸Fundación Parque Científico de Madrid
- ¹⁰⁹Centro de Coordinación de Alertas y Emergencias Sanitarias, Ministerio de Sanidad, Madrid
- ¹¹⁰Laboratorio de microbiología del Hospital Comarcal de Vinaròs

List of the SeqCOVID-SPAIN consortium members

Álvaro Chiner-Oms¹, Irving Cancino-Muñoz¹, Mariana G. López¹, Manoli Torres-Puente¹, Inmaculada Gómez-Navarro¹, Santiago Jiménez-Serrano¹, Jordi Pérez-Tur¹, Darío García de Viedma^{2,3,4}, Laura Pérez-Lago^{2,3}, Marta Herranz^{2,3,4}, Jon Sicilia^{2,3}, Pilar Catalán-Alonso^{2,3,4}, Julia Suárez González³, Patricia Muñoz^{2,3,4}, Mireia Coscolla⁵, Paula Ruiz-Rodríguez⁵, Fernando González-Candelas^{6,7}, Iñaki Comas^{1,7}, Lidia Ruiz-Roldán⁶, María Alma Bracho^{6,7}, Neris García-González⁶, Lúcia Martínez Priego⁸, Inmaculada Galán-Vendrell⁸, Paula Ruiz-Hueso⁸, Griselda De Marco⁸, Loreto Ferrús-Abad Ma⁸, Sandra CarbóRamírez⁸, Giuseppe D'Auria^{7,8}, Galo Adrian Goig⁹, Juan Alberola^{10,11,12}, Jose Miguel Nogueira^{10,11,12}, Juan José Camarena^{10,11,12}, David Navarro^{12,13}, Eliseo Albert¹³, Ignacio Torres¹³, Maitane Aranzamendi Zaldumbide^{14,15}, Óscar Martínez Expósito^{14,15}, Nerea Antona Urieta^{14,15}, María de Toro¹⁶, María Pilar BeaEscudero¹⁶, Jose

Antonio Boga^{17,18}, Cristian Castelló-Abietar^{17,18}, Susana Rojo-Alba^{17,18}, Marta Elena Álvarez-Argüelles^{17,18}, Santiago Melón^{17,18}, Elisa Martró^{7,19}, Antoni E. Bordoy¹⁹, Anna Not¹⁹, Adrián Antuori¹⁹, Anabel Fernández-Navarro¹⁹, Andrés Canut-Blasco²⁰, Silvia Hernáez Crespo²⁰, Maria Luz Cordón Rodríguez²⁰, Maria Concepción Lecaroz Agara²⁰, Carmen Gómez-González²⁰, Amaia AguirreQuiñonero²⁰, José Israel López-Mirones²⁰, Marina Fernández-Torres²⁰, Maria Rosario Almela-Ferrer²⁰, Ana Carvajal²¹, Juan Miguel Fregeneda-Grandes²¹, Héctor Argüello²¹, Gustavo Cilla Eguiluz²², Milagrosa Montes Ros²², Luis Piñeiro Vázquez²², Ane Sorarrain²², José María Marimón²², José J. Costa-Alcalde²³, Rocío Trastoy²³, Gema Barbeito Castiñeiras²³, Amparo Coira²³, María Luisa Pérez del Molino²³, Antonio Aguilera²³, Begoña Palop-Borrás²⁴, Inmaculada de Toro Peinado²⁴, Maria Concepción Mediavilla Gradolph²⁴, Mercedes Pérez-Ruiz²⁴, Mirian Fernández-Alonso²⁵, Jose Luis del Pozo²⁵, Oscar GonzálezRecio²⁷, Mónica Gutiérrez-Rivas²⁷, Jovita Fernández-Pinero²⁷, Miguel Ángel Jiménez Clavero²⁷, Begoña Fuster Escrivá^{12,28}, Concepción Gimeno Cardona²⁸, María Dolores Ocete Mochón²⁸, Rafael Medina-Gonzalez²⁸, José Antonio Lepe²⁹, Verónica González Galán²⁹, Ángel Rodríguez-Villodres²⁹, Nieves Gonzalo Jiménez³⁰, Jordi Reina³¹, Carla López-Causapé³¹, Maria Dolores Gómez-Ruiz³², Eva M. Gonzalez-Barbera³², José Luis López-Hontangas³², Vicente Martín^{7,33}, Antonio J. Molina³³, Tania Fernandez-Villa³³, Ana Milagro Beamonte³⁴, Nieves Felisa Martínez-Cameo³⁴, Yolanda GraciaGrataloup³⁴, Rosario Moreno-Muñoz³⁵, Maria Dolores Tirado Balaguer³⁵, José María Navarro-Marí^{36,37}, Irene Pedrosa-Corral^{36,37}, Sara Sanbonmatsu-Gámez^{36,37}, Antonio Oliver^{31,38}, Mónica Parra Grande³⁹, Bárbara Gómez Alonso³⁹, Francisco José Arjona Zaragoza³⁹, Maria Carmen Pérez González⁴⁰, Francisco Javier Chamizo López⁴⁰, Ana Bordes-Benítez⁴⁰, Núria Rabella^{41,42,43}, Ferran Navarro^{41,42,43}, Elisenda Miró^{41,42}, Antonio Rezusta^{34,44,45}, Alexander Tristancho^{34,44}, Encarnación Simarro Córdoba⁴⁶, Julia Lozano-Serra⁴⁶, Lorena Robles Fonseca⁴⁶, Álex Soriano⁴⁷, Francisco Javier Roig Sena⁴⁸, Hermelinda Vanaclocha Luna⁴⁸, Isabel Sanmartín⁴⁹, Daniel García-Souto^{50,51,52}, Ana Pequeño-Valtierra⁵⁰, Jose M. C. Tubio^{50,51}, Javier Temes^{50,51}, Jorge Rodríguez-Castro⁵⁰, Martín Santamarina García⁵⁰, Manuel RodríguezIglesias^{53,54,55}, Fátima Galán-Sanchez^{53,54,55}, Salud Rodríguez-Pallares^{53,54}, José Manuel AzconaGutiérrez⁵⁶, Miriam Blasco-Alberdi⁵⁶, Alfredo Mayor^{7,57,58}, Alberto L. García-Basteiro^{57,58}, Gemma Moncunill⁵⁷, Carlota Dobaño⁵⁷, Pau Cisteró⁵⁷, Oriol Mitjà^{59,60}, Camila González-Beiras⁵⁹, Martí Vall-Mayans⁵⁹, Marc Corbacho-Monné⁵⁹, Andrea Alemany⁵⁹, Cristina Muñoz-Cuevas^{61,62}, Guadalupe Rodríguez-Rodríguez^{61,62}, Rafael Benito^{45,63}, Sonia Algarate⁶³, Jessica Bueno⁶³, Andrea VergaraGómez⁶⁴, Miguel J. Martínez^{57,65,66}, Jordi Vila^{57,65}, Elisa Rubio^{57,65}, Aida Peiró-Mestres^{57,65}, Jessica Navero-Castillejos^{57,65}, David Posada^{67,68,69}, Diana Valverde^{67,68,69}, Nuria Estévez⁶⁷, Iria FernándezSilva^{67,68}, Loretta de Chiara^{67,68}, Pilar Gallego-García⁶⁷, Nair Varela⁶⁷, Ulises Gómez-Pinedo⁷⁰, Mónica Gozalo-Margüello⁷¹, Maria Eliecer Cano García⁷¹, José Manuel Méndez-Legaza⁷¹, Jesus RodríguezLozano⁷¹, María Siller⁷¹, Daniel Pablo-

Marcos⁷¹, Maria Montserrat Ruiz-García^{30,72}, Antonio Galiana⁷³, Judith Sánchez-Almendro⁷³, Maria Isabel Gascón Ros⁷⁴, Cristina Juana Torregrosa-Hetland⁷⁴, Eva María Pastor Boix⁷⁴, Paloma Cascales Ramos⁷⁴, Pedro Luis Garcinuño Enríquez⁷⁴, Salvador Raga Borja⁷⁴, Julia González Cantó⁷⁵, Olalla Martínez Macías⁷⁵, Adolfo de Salazar⁷⁶, Laura Viñuela González⁷⁶, Natalia Chueca⁷⁶, Federico García⁷⁶, Cristina Gómez-Camarasa⁷⁶, Amparo Farga Martí⁷⁷, Rocío Falcón⁷⁷, Victoria Domínguez-Márquez⁷⁷, Anna M. Planas⁷⁸, Israel Fernández-Cádenas⁷⁹, Maria Ángeles Marcos⁸⁰, Carmen Ezpeleta^{81,82}, Ana Navascués^{81,82}, Ana Miqueleiz Zapatero⁸¹, Manuel Segovia^{83,84}, Antonio Moreno-Docón^{83,84}, Esther Viedma⁸⁵, Raúl Recio Martínez⁸⁵, Irene Muñoz-Gallego⁸⁵, Sara Gonzalez-Bodi⁸⁵, Maria Dolores Folgueira⁸⁵, Jesús Mingorance⁸⁶, Elías Dahdouh⁸⁶, Fernando Lázaro-Perona⁸⁶, María Rodríguez-Tejedor⁸⁶, María Pilar Romero-Gómez⁸⁶, Julio García-Rodríguez⁸⁶, Juan Carlos Galán⁸⁷, Mario Rodríguez-Dominguez^{7,87,88}, Laura Martínez-García^{7,87,88}, Melanie Abreu Di Berardino^{87,88}, Manuel Ponce-Alonso^{87,88,89}, Jose Maria González-Alba^{87,88}, Ivan Sanz-Muñoz⁹⁰, Diana Pérez San José⁹⁰, Maria Gil Fortuño⁹¹, Juan B. Bellido-Blasco⁹¹, Alberto Yagüe Muñoz⁹¹, Noelia Henández Pérez⁹¹, Helena Buj Jordá⁹¹, Óscar Pérez Olaso⁹¹, Alejandro González Praetorius⁹², Nora Mariela Martínez Ramírez⁹², Aida Ramírez Marinero⁹³, Eduardo Padilla León⁹³, Alba Vilas Basil⁹³, Mireia Canal Aranda⁹³, Albert Bernet Sánchez⁹⁴, Alba Bellés Bellés⁹⁴, Eric López González⁹⁴, Iván Prats Sánchez⁹⁴, Mercè García-González⁹⁴, Miguel José Martínez-Lirola⁹⁵, Manuel Ángel Rodríguez Maresca⁹⁵, Maria Teresa Cabezas Fernández⁹⁵, María Eugenia Carrillo Gil⁹⁵, Maria Paz Ventero Martín⁹⁶, Carmen Molina Pardines⁹⁶, Nieves Orta Mira⁹⁷, María Navarro Cots⁹⁷, Inmaculada Vidal Catalá⁹⁷, Isabel García Nava⁹⁷, Soledad Illescas Fernández Bermejo^{98,99}, José Martínez-Alarcón^{98,99}, Marta Torres-Narbona⁹⁸, Cristina Colmenarejo⁹⁸, Lidia García Agudo⁹⁸, Jorge A. Pérez García⁹⁸, Martín Yago López¹⁰⁰, María Ángeles Goberna Bravo¹⁰⁰, Victoria Simón García¹⁰¹, Gonzalo Llop Furquet¹⁰¹, Agustín Iranzo Tatay¹⁰¹, Sandra Moreno-Marro¹⁰¹, Noelia Lozano Rodríguez¹⁰¹, Amparo Broseta Tamarit¹⁰², Juan José Badiola Díez¹⁰³, Amparo Martínez Ramírez¹⁰⁴, Ana Dopazo¹⁰⁵, Sergio Callejas¹⁰⁵, Alberto Benguría¹⁰⁵, Begoña Aguado¹⁰⁶, Antonio Alcamí¹⁰⁶, Marta Bermejo Bermejo¹⁰⁷, Ricardo Ramos-Ruiz¹⁰⁸, Víctor Manuel Fernández Soria¹⁰⁸, Fernando Simón Soria¹⁰⁹, Mercedes Roig Cardells¹¹⁰

⁴⁸Servicio de Vigilancia y Control Epidemiológico. Dirección General de Salud Pública y Adicciones. Conselleria de Sanitat Universal i Salut Pública. Generalitat Valenciana. Valencia, Spain

⁴⁹Real Jardín Botánico, Consejo Superior de Investigaciones Científicas

⁵⁰Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain

⁵¹Department of Zoology, Genetics and Physical Anthropology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain

- ⁵²Cancer Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Cambridge CB1 8PS, UK**
- ⁵³Servicio de Microbiología, H.U. Puerta del Mar, Cádiz, Spain**
- ⁵⁴INIBICA, Instituto de Investigación Biomédica de Cádiz, Cádiz, Spain**
- ⁵⁵Departamento de Biomedicina, Biotecnología y Salud Pública. Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain**
- ⁵⁶Laboratorio de Microbiología. Hospital San Pedro, Logroño, Spain**
- ⁵⁷ISGlobal, Barcelona Institute for Global Health, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain**
- ⁵⁸Centro de Investigaçã em Saúde de Manhica (CISM), Maputo, Mozambique**
- ⁵⁹Fight AIDS and Infectious Diseases Foundation, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, 08916 Badalona, Barcelona, Spain**
- ⁶⁰Lihir Medical Centre-InternationalSOS, Lihir Island, Papua New Guinea**
- ⁶¹Servicio de Microbiología Clínica. Hospital San Pedro de Alcántara, Cáceres, Spain**
- ⁶²Servicio Extremeño de Salud, Spain**
- ⁶³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain**
- ⁶⁴Servicio de Microbiología & CORE de Biología Molecular, CDB, Hospital Clínic, Barcelona, Spain**
- ⁶⁵Department of Microbiology - CDB, Hospital Clínic de Barcelona**
- ⁶⁶University of Barcelona, Barcelona, Spain**
- ⁶⁷CINBIO, Universidade de Vigo, Vigo, Spain**
- ⁶⁸Department of Biochemistry, Genetics, and Immunology, Universidade de Vigo, Vigo, Spain**
- ⁶⁹Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Spain**
- ⁷⁰IdISSC/Hospital Clínico San Carlos, Madrid, Spain**
- ⁷¹ Hospital Marqués de Valdecilla - IDIVAL, Santander, Spain**
- ⁷²Departamento de Producción Vegetal y Microbiología. Universidad Miguel Hernández. Elche**
- ⁷³Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana: Elche, Alicante, ES, (Hospital General Universitario de Elche, Microbiologia)**
- ⁷⁴Laboratorio de Microbiología. Hospital General Universitario de Elda. Elda, Alicante, Spain**

- ⁷⁵Laboratorio Biología Molecular, Área de Diagnóstico Biológico, Hospital Universitario La Ribera, Alzira, Valencia, Spain**
- ⁷⁶Hospital Universitario San Cecilio, Granada, Spain**
- ⁷⁷Servicio de Microbiología, Hospital Arnau de Vilanova, Valencia, Spain**
- ⁷⁸Biomedical Research Institute of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain**
- ⁷⁹Sant Pau Hospital Research Institute, Barcelona, Spain**
- ⁸⁰Microbiology Department, Hospital Clinic I Provincial de Barcelona. Institut of Global Health of Barcelona (ISGlobal), Barcelona, Spain**
- ⁸¹Servicio de Microbiología Clínica, Complejo Hospitalario de Navarra (Pamplona, Navarra)**
- ⁸²Instituto de Investigación Sanitaria de Navarra (IdiSNA)**
- ⁸³Servicio de Microbiología, Hospital Clínico Universitario Virgen de la Arrixaca, Spain**
- ⁸⁴Departamento de Genética y Microbiología, Universidad de Murcia, Carretera Madrid-Cartagena sn,30120-El Palmar, Murcia, Spain**
- ⁸⁵Hospital Universitario 12 de Octubre, Madrid, Spain**
- ⁸⁶Hospital Universitario La Paz, IdiPAZ, Madrid, Spain**
- ⁸⁷Servicio de Microbiología. Hospital Universitario Ramón y Cajal, Madrid, Spain**
- ⁸⁸Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)**
- ⁸⁹Red Española de Investigación en Patología Infecciosa (REIPI)**
- ⁹⁰Centro Nacional de Gripe, Valladolid, Spain**
- ⁹¹Hospital Universitari de La Plana, Vila-Real, Spain**
- ⁹²Hospital Universitario de Guadalajara, Guadalajara, Spain**
- ⁹³Laboratori de Referència de Catalunya, Spain**
- ⁹⁴Hospital Universitari Arnau de Vilanova de Lleida, Spain**
- ⁹⁵Complejo Hospitalario Universitario Torrecárdenas, Almería, Spain**
- ⁹⁶Servicio de Microbiología. Hospital General Universitario de Alicante. Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL). Alicante, Spain**
- ⁹⁷Hospital Francisc de Borja, Sección Microbiología, Spain**
- ⁹⁸Hospital General Universitario de Ciudad Real, Spain**
- ⁹⁹Facultad de Medicina de Ciudad Real. UCLM**

- ¹⁰⁰Hospital General de Requena, Spain**
- ¹⁰¹Laboratorio de Biología Molecular. Servicio de Análisis Clínicos y Microbiología. Hospital de Sagunto**
- ¹⁰²Synlab - Hospital de Manises, Spain**
- ¹⁰³Centro de Encefalopatías y Enfermedades Transmisibles Emergentes, Facultad de Veterinaria, Universidad de Zaragoza, Zaragoza, Spain**
- ¹⁰⁴Universitat de València, Servei Cental de Suport a la Investigació Experimental (SCSIE), Sección de Genómica, València, Spain**
- ¹⁰⁵Centro Nacional de Investigaciones Cardiovasculares (CNIC)**
- ¹⁰⁶Centro de Biología Molecular Severo Ochoa (CBMSO) (CSIC-UAM), Nicolás Cabrera 1, Cantoblanco, 28049 Madrid, Spain**
- ¹⁰⁷Unidad de Vigilancia de Salud y Medicina del Trabajo CSIC. Serrano 113p, 28006 Madrid. Spain**
- ¹⁰⁸Fundación Parque Científico de Madrid**
- ¹⁰⁹Centro de Coordinación de Alertas y Emergencias Sanitarias, Ministerio de Sanidad, Madrid**
- ¹¹⁰Laboratorio de microbiología del Hospital Comarcal de Vinaròs**

Álvaro Chiner-Oms¹, Irving Cancino-Muñoz¹, Mariana G. López¹, Manoli Torres-Puente¹, Inmaculada Gómez-Navarro¹, Santiago Jiménez-Serrano¹, Jordi Pérez-Tur¹, Darío García de Viedma^{2,3,4}, Laura Pérez-Lago^{2,3}, Marta Herranz^{2,3,4}, Jon Sicilia^{2,3}, Pilar Catalán-Alonso^{2,3,4}, Julia Suárez González³, Patricia Muñoz^{2,3,4}, Mireia Coscolla⁵, Paula Ruiz-Rodríguez⁵, Fernando González-Candelas^{6,7}, Iñaki Comas^{1,7}, Lidia Ruiz-Roldán⁶, María Alma Bracho^{6,7}, Neris García-González⁶, Lúcia Martínez Priego⁸, Inmaculada Galán-Vendrell⁸, Paula Ruiz-Hueso⁸, Griselda De Marco⁸, Loreto Ferrús-Abad Ma⁸, Sandra CarbóRamírez⁸, Giuseppe D'Auria^{7,8}, Galo Adrian Goig⁹, Juan Alberola^{10,11,12}, Jose Miguel Nogueira^{10,11,12}, Juan José Camarena^{10,11,12}, David Navarro^{12,13}, Eliseo Albert¹³, Ignacio Torres¹³, Maitane Aranzamendi Zaldumbide^{14,15}, Óscar Martínez Expósito^{14,15}, Nerea Antona Urieta^{14,15}, María de Toro¹⁶, María Pilar BeaEscudero¹⁶, Jose Antonio Boga^{17,18}, Cristian Castelló-Abietar^{17,18}, Susana Rojo-Alba^{17,18}, Marta Elena Álvarez-Argüelles^{17,18}, Santiago Melón^{17,18}, Elisa Martró^{7,19}, Antoni E. Bordoy¹⁹, Anna Not¹⁹, Adrián Antuori¹⁹, Anabel Fernández-Navarro¹⁹, Andrés Canut-Blasco²⁰, Silvia Hernández Crespo²⁰, Maria Luz Cordón Rodríguez²⁰, Maria Concepción Lecaroz Agara²⁰, Carmen Gómez-González²⁰, Amaia AguirreQuiñonero²⁰, José Israel López-Mirones²⁰, Marina Fernández-Torres²⁰, Maria Rosario Almela-Ferrer²⁰, Ana Carvajal²¹, Juan Miguel Fregeneda-Grandes²¹, Héctor Argüello²¹, Gustavo Cilla Eguiluz²², Milagrosa Montes Ros²², Luis Piñeiro Vázquez²², Ane Sorarrain²², José María Marimón²², José J. Costa-Alcalde²³, Rocío Trastoy²³, Gema Barbeito Castiñeiras²³, Amparo Coira²³, María Luisa Pérez del Molino²³, Antonio Aguilera²³, Begoña Palop-Borrás²⁴, Inmaculada de Toro Peinado²⁴, Maria

Concepción Mediavilla Gradolph²⁴, Mercedes Pérez-Ruiz²⁴, Mirian Fernández-Alonso²⁵, Jose Luis del Pozo²⁵, Oscar GonzálezRecio²⁷, Mónica Gutiérrez-Rivas²⁷, Jovita Fernández-Pinero²⁷, Miguel Ángel Jiménez Clavero²⁷, Begoña Fuster Escrivá^{12,28}, Concepción Gimeno Cardona²⁸, María Dolores Ocete Mochón²⁸, Rafael Medina-Gonzalez²⁸, José Antonio Lepe²⁹, Verónica González Galán²⁹, Ángel Rodríguez-Villodres²⁹, Nieves Gonzalo Jiménez³⁰, Jordi Reina³¹, Carla López-Causapé³¹, María Dolores Gómez-Ruiz³², Eva M. Gonzalez-Barbera³², José Luis López-Hontangas³², Vicente Martín^{7,33}, Antonio J. Molina³³, Tania Fernandez-Villa³³, Ana Milagro Beamonte³⁴, Nieves Felisa Martínez-Cameo³⁴, Yolanda GraciaGataloup³⁴, Rosario Moreno-Muñoz³⁵, María Dolores Tirado Balaguer³⁵, José María Navarro-Marí^{36,37}, Irene Pedrosa-Corral^{36,37}, Sara Sanbonmatsu-Gámez^{36,37}, Antonio Oliver^{31,38}, Mónica Parra Grande³⁹, Bárbara Gómez Alonso³⁹, Francisco José Arjona Zaragoza³⁹, María Carmen Pérez González⁴⁰, Francisco Javier Chamizo López⁴⁰, Ana Bordes-Benítez⁴⁰, Núria Rabella^{41,42,43}, Ferran Navarro^{41,42,43}, Elisenda Miró^{41,42}, Antonio Rezusta^{34,44,45}, Alexander Tristancho^{34,44}, Encarnación Simarro Córdoba⁴⁶, Julia Lozano-Serra⁴⁶, Lorena Robles Fonseca⁴⁶, Álex Soriano⁴⁷, Francisco Javier Roig Sena⁴⁸, Hermelinda Vanaclocha Luna⁴⁸, Isabel Sanmartín⁴⁹, Daniel García-Souto^{50,51,52}, Ana Pequeño-Valtierra⁵⁰, Jose M. C. Tubio^{50,51}, Javier Temes^{50,51}, Jorge Rodríguez-Castro⁵⁰, Martín Santamarina García⁵⁰, Manuel RodríguezIglesias^{53,54,55}, Fátima Galán-Sanchez^{53,54,55}, Salud Rodríguez-Pallares^{53,54}, José Manuel AzconaGutiérrez⁵⁶, Miriam Blasco-Alberdi⁵⁶, Alfredo Mayor^{7,57,58}, Alberto L. García-Basteiro^{57,58}, Gemma Moncunill⁵⁷, Carlota Dobaño⁵⁷, Pau Cisteró⁵⁷, Oriol Mitjà^{59,60}, Camila González-Beiras⁵⁹, Martí Vall-Mayans⁵⁹, Marc Corbacho-Monné⁵⁹, Andrea Alemany⁵⁹, Cristina Muñoz-Cuevas^{61,62}, Guadalupe Rodríguez-Rodríguez^{61,62}, Rafael Benito^{45,63}, Sonia Algarate⁶³, Jessica Bueno⁶³, Andrea VergaraGómez⁶⁴, Miguel J. Martínez^{57,65,66}, Jordi Vila^{57,65}, Elisa Rubio^{57,65}, Aida Peiró-Mestres^{57,65}, Jessica Navero-Castillejos^{57,65}, David Posada^{67,68,69}, Diana Valverde^{67,68,69}, Nuria Estévez⁶⁷, Iria FernándezSilva^{67,68}, Loretta de Chiara^{67,68}, Pilar Gallego-García⁶⁷, Nair Varela⁶⁷, Ulises Gómez-Pinedo⁷⁰, Mónica Gozalo-Margüello⁷¹, María Eliecer Cano García⁷¹, José Manuel Méndez-Legaza⁷¹, Jesus RodríguezLozano⁷¹, María Siller⁷¹, Daniel Pablo-Marcos⁷¹, María Montserrat Ruiz-García^{30,72}, Antonio Galiana⁷³, Judith Sánchez-Almendro⁷³, María Isabel Gascón Ros⁷⁴, Cristina Juana Torregrosa-Hetland⁷⁴, Eva María Pastor Boix⁷⁴, Paloma Cascales Ramos⁷⁴, Pedro Luis Garcinuño Enríquez⁷⁴, Salvador Raga Borja⁷⁴, Julia González Cantó⁷⁵, Olalla Martínez Macias⁷⁵, Adolfo de Salazar⁷⁶, Laura Viñuela González⁷⁶, Natalia Chueca⁷⁶, Federico García⁷⁶, Cristina Gómez-Camarasa⁷⁶, Amparo Farga Martí⁷⁷, Rocío Falcón⁷⁷, Victoria Domínguez-Márquez⁷⁷, Anna M. Planas⁷⁸, Israel Fernández-Cádenas⁷⁹, María Ángeles Marcos⁸⁰, Carmen Ezpeleta^{81,82}, Ana Navascués^{81,82}, Ana Miqueleiz Zapatero⁸¹, Manuel Segovia^{83,84}, Antonio Moreno-Docón^{83,84}, Esther Viedma⁸⁵, Raúl Recio Martínez⁸⁵, Irene Muñoz-Gallego⁸⁵, Sara Gonzalez-Bodi⁸⁵, María Dolores Folgueira⁸⁵, Jesús Mingorance⁸⁶, Elias Dahdouh⁸⁶, Fernando Lázaro-Perona⁸⁶, María Rodríguez-Tejedor⁸⁶, María Pilar Romero-Gómez⁸⁶, Julio García-Rodríguez⁸⁶, Juan Carlos Galán⁸⁷, Mario Rodríguez-Dominguez^{7,87,88},

Laura Martínez-García^{7,87,88}, Melanie Abreu Di Berardino^{87,88}, Manuel Ponce-Alonso^{87,88,89}, Jose Maria González-Alba^{87,88}, Ivan Sanz-Muñoz⁹⁰, Diana Pérez San José⁹⁰, Maria Gil Fortuño⁹¹, Juan B. Bellido-Blasco⁹¹, Alberto Yagüe Muñoz⁹¹, Noelia Henández Pérez⁹¹, Helena Buj Jordá⁹¹, Óscar Pérez Olaso⁹¹, Alejandro González Praetorius⁹², Nora Mariela Martínez Ramírez⁹², Aida Ramírez Marinero⁹³, Eduardo Padilla León⁹³, Alba Vilas Basil⁹³, Mireia Canal Aranda⁹³, Albert Bernet Sánchez⁹⁴, Alba Bellés Bellés⁹⁴, Eric López González⁹⁴, Iván Prats Sánchez⁹⁴, Mercè García-González⁹⁴, Miguel José Martínez-Lirola⁹⁵, Manuel Ángel Rodríguez Maresca⁹⁵, Maria Teresa Cabezas Fernández⁹⁵, María Eugenia Carrillo Gil⁹⁵, Maria Paz Ventero Martín⁹⁶, Carmen Molina Pardines⁹⁶, Nieves Orta Mira⁹⁷, María Navarro Cots⁹⁷, Inmaculada Vidal Catalá⁹⁷, Isabel García Nava⁹⁷, Soledad Illescas FernándezBermejo^{98,99}, José Martínez-Alarcón^{98,99}, Marta Torres-Narbona⁹⁸, Cristina Colmenarejo⁹⁸, Lidia GarcíaAgudo⁹⁸, Jorge A. Pérez García⁹⁸, Martín Yago López¹⁰⁰, María Ángeles Goberna Bravo¹⁰⁰, Victoria Simón García¹⁰¹, Gonzalo Llop Furquet¹⁰¹, Agustín Iranzo Tatay¹⁰¹, Sandra Moreno-Marro¹⁰¹, Noelia Lozano Rodríguez¹⁰¹, Amparo Broseta Tamarit¹⁰², Juan José Badiola Díez¹⁰³, Amparo MartínezRamírez¹⁰⁴, Ana Dopazo¹⁰⁵, Sergio Callejas¹⁰⁵, Alberto Benguría¹⁰⁵, Begoña Aguado¹⁰⁶, Antonio Alcamí¹⁰⁶, Marta Bermejo Bermejo¹⁰⁷, Ricardo Ramos-Ruíz¹⁰⁸, Víctor Manuel Fernández Soria¹⁰⁸, Fernando Simón Soria¹⁰⁹, Mercedes Roig Cardells¹¹⁰

Mireia Coscolla^{5,*}, **Fernando González-Candelas**^{6,7,*}, **Iñaki Comas**^{1,7,*}

Affiliations

⁴⁸Servicio de Vigilancia y Control Epidemiológico. Dirección General de Salud Pública y Adicciones. Conselleria de Sanitat Universal i Salut Pública. Generalitat Valenciana. Valencia, Spain

⁴⁹Real Jardín Botánico, Consejo Superior de Investigaciones Científicas

⁵⁰Genomes and Disease, Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain

⁵¹Department of Zoology, Genetics and Physical Anthropology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain

⁵²Cancer Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Cambridge CB1 8PS, UK

⁵³Servicio de Microbiología, H.U. Puerta del Mar, Cádiz, Spain

⁵⁴INIBICA, Instituto de Investigación Biomédica de Cádiz, Cádiz, Spain

⁵⁵Departamento de Biomedicina, Biotecnología y Salud Pública. Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain

⁵⁶Laboratorio de Microbiología. Hospital San Pedro, Logroño, Spain

⁵⁷ISGlobal, Barcelona Institute for Global Health, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain

- ⁵⁸Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique
- ⁵⁹Fight AIDS and Infectious Diseases Foundation, Hospital Germans Trias i Pujol, Carretera de Canyet, s/n, 08916 Badalona, Barcelona, Spain
- ⁶⁰Lihir Medical Centre-InternationalSOS, Lihir Island, Papua New Guinea
- ⁶¹Servicio de Microbiología Clínica. Hospital San Pedro de Alcántara, Cáceres, Spain
- ⁶²Servicio Extremeño de Salud, Spain
- ⁶³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
- ⁶⁴Servicio de Microbiología & CORE de Biología Molecular, CDB, Hospital Clínic, Barcelona, Spain
- ⁶⁵Department of Microbiology - CDB, Hospital Clínic de Barcelona
- ⁶⁶University of Barcelona, Barcelona, Spain
- ⁶⁷CINBIO, Universidade de Vigo, Vigo, Spain
- ⁶⁸Department of Biochemistry, Genetics, and Immunology, Universidade de Vigo, Vigo, Spain
- ⁶⁹Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Spain
- ⁷⁰IdISSC/Hospital Clínico San Carlos, Madrid, Spain
- ⁷¹ Hospital Marqués de Valdecilla - IDIVAL, Santander, Spain
- ⁷²Departamento de Producción Vegetal y Microbiología. Universidad Miguel Hernández. Elche
- ⁷³Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana: Elche, Alicante, ES, (Hospital General Universitario de Elche, Microbiología)
- ⁷⁴Laboratorio de Microbiología. Hospital General Universitario de Elda. Elda, Alicante, Spain
- ⁷⁵Laboratorio Biología Molecular, Área de Diagnóstico Biológico, Hospital Universitario La Ribera, Alzira, Valencia, Spain
- ⁷⁶Hospital Universitario San Cecilio, Granada, Spain
- ⁷⁷Servicio de Microbiología, Hospital Arnau de Vilanova, Valencia, Spain
- ⁷⁸Biomedical Research Institute of Barcelona (IIBB), Spanish National Research Council (CSIC), Barcelona, Spain
- ⁷⁹Sant Pau Hospital Research Institute, Barcelona, Spain
- ⁸⁰Microbiology Department, Hospital Clínic I Provincial de Barcelona. Institut of Global Health of Barcelona (ISGlobal), Barcelona, Spain

- ⁸¹Servicio de Microbiología Clínica, Complejo Hospitalario de Navarra (Pamplona, Navarra)
- ⁸²Instituto de Investigación Sanitaria de Navarra (IdiSNA)
- ⁸³Servicio de Microbiología, Hospital Clínico Universitario Virgen de la Arrixaca, Spain
- ⁸⁴Departamento de Genética y Microbiología, Universidad de Murcia, Carretera Madrid-Cartagena sn,30120-El Palmar, Murcia, Spain
- ⁸⁵Hospital Universitario 12 de Octubre, Madrid, Spain
- ⁸⁶Hospital Universitario La Paz, IdiPAZ, Madrid, Spain
- ⁸⁷Servicio de Microbiología. Hospital Universitario Ramón y Cajal, Madrid, Spain
- ⁸⁸Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)
- ⁸⁹Red Española de Investigación en Patología Infecciosa (REIPI)
- ⁹⁰Centro Nacional de Gripe, Valladolid, Spain
- ⁹¹Hospital Universitari de La Plana, Vila-Real, Spain
- ⁹²Hospital Universitario de Guadalajara, Guadalajara, Spain
- ⁹³Laboratori de Referència de Catalunya, Spain
- ⁹⁴Hospital Universitari Arnau de Vilanova de Lleida, Spain
- ⁹⁵Complejo Hospitalario Universitario Torrecárdenas, Almería, Spain
- ⁹⁶Servicio de Microbiología. Hospital General Universitario de Alicante. Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL). Alicante, Spain
- ⁹⁷Hospital Francesc de Borja, Sección Microbiología, Spain
- ⁹⁸Hospital General Universitario de Ciudad Real, Spain
- ⁹⁹Facultad de Medicina de Ciudad Real. UCLM
- ¹⁰⁰Hospital General de Requena, Spain
- ¹⁰¹Laboratorio de Biología Molecular. Servicio de Análisis Clínicos y Microbiología. Hospital de Sagunto
- ¹⁰²Synlab - Hospital de Manises, Spain
- ¹⁰³Centro de Encefalopatías y Enfermedades Transmisibles Emergentes, Facultad de Veterinaria, Universidad de Zaragoza, Zaragoza, Spain
- ¹⁰⁴Universitat de València, Servei Cental de Suport a la Investigació Experimental (SCSIE), Sección de Genómica, València, Spain
- ¹⁰⁵Centro Nacional de Investigaciones Cardiovasculares (CNIC)
- ¹⁰⁶Centro de Biología Molecular Severo Ochoa (CBMSO) (CSIC-UAM), Nicolás Cabrera 1, Cantoblanco, 28049 Madrid, Spain

- ¹⁰⁷Unidad de Vigilancia de Salud y Medicina del Trabajo CSIC. Serrano 113p, 28006 Madrid. Spain
- ¹⁰⁸Fundación Parque Científico de Madrid
- ¹⁰⁹Centro de Coordinación de Alertas y Emergencias Sanitarias, Ministerio de Sanidad, Madrid
- ¹¹⁰Laboratorio de microbiología del Hospital Comarcal de Vinaròs
- ¹Instituto de Biomedicina de Valencia (IBV-CSIC), Valencia, Spain
- ²Servicio de Microbiología Clínica y Enfermedades Infecciosas. Hospital General Universitario Gregorio Marañón, Madrid, Spain
- ³Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
- ⁴CIBER Enfermedades Respiratorias (CIBERES)
- ⁵Instituto de Biología Integrativa de Sistemas, I2SysBio (CSIC-Universitat de València), Valencia, Spain
- ⁶Joint Research Unit “Infection and Public Health” FISABIO-University of Valencia I2SysBio, Valencia, Spain
- ⁷Ciber en Epidemiología y Salud Pública (CIBERESP)
- ⁸FISABIO, Servicio de Secuenciación, València, Spain
- ⁹Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland
- ¹⁰Servicio de Microbiología. Hospital Dr Peset, Valencia, Spain
- ¹¹Conselleria de Sanitat i Consum. Generalitat Valenciana, Spain
- ¹²Universitat de València, Facultad de Medicina, Departamento Microbiología, Valencia, Spain
- ¹³Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain
- ¹⁴Servicio de Microbiología, Hospital Universitario Cruces, Bilbao, Spain
- ¹⁵Grupo de Microbiología y Control de Infección Instituto de Investigación Sanitaria Biocruces Bizkaia, Spain
- ¹⁶Plataforma de Genómica y Bioinformática, Centro de Investigación Biomédica de La Rioja (CIBIR), Logroño, Spain
- ¹⁷Servicio de Microbiología, Hospital Universitario Central de Asturias, Oviedo, Spain
- ¹⁸Grupo de Microbiología Traslacional Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain

- ¹⁹Servicio de Microbiología, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Barcelona, Spain
- ²⁰Servicio de Microbiología, Hospital Universitario de Álava, Osakidetza-Servicio Vasco de Salud, Vitoria-Gasteiz (Álava), Spain
- ²¹Animal Health Department. Universidad de León, León, Spain
- ²²Biodonostia; Osakidetza, Hospital Universitario Donostia, Servicio de Microbiología, San Sebastián, Spain
- ²³Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
- ²⁴Servicio de Microbiología, Hospital Regional Universitario de Málaga, Málaga, Spain
- ²⁵Servicio de Enfermedades Infecciosas y Microbiología clínica. Clínica Universidad de Navarra, Pamplona, Spain
- ²⁶Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia
- ²⁷Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, O.A., M.P. - INIA, Madrid, Spain
- ²⁸Servicio de Microbiología. Consorcio Hospital General Universitario de Valencia, Valencia, Spain
- ²⁹Servicio de Microbiología UCEIMP, Hospital Universitario Virgen del Rocío, Sevilla, Spain
- ³⁰Servicio Microbiología, Departamento de Salud de Elche-Hospital General, Elche, Alicante, Spain
- ³¹Servicio de Microbiología, Hospital Universitario Son Espases, Palma de Mallorca, Spain
- ³²Hospital Universitario y Politécnico La Fe, Servicio de Microbiología, Valencia, Spain
- ³³Research Group on Gene-Environment Interactions and Health. Institute of Biomedicine (IBIOMED). Universidad de León, León, Spain
- ³⁴Servicio de Microbiología Clínica Hospital Universitario Miguel Servet, Zaragoza, Spain
- ³⁵Hospital General Universitario de Castellón, Castellón, Spain
- ³⁶Servicio de Microbiología. Hospital Universitario Virgen de las Nieves, Granada, Spain
- ³⁷Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria ibs, Granada, Spain

- ³⁸Instituto de Investigación Sanitaria de las Islas Baleares, Spain
- ³⁹Laboratorio de Microbiología, Hospital Marina Baixa. Villajoyosa, Spain
- ⁴⁰Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain
- ⁴¹Servei de Microbiologia. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- ⁴²CREPIMC. Institut d'Investigació Biomèdica Sant Pau, Barcelona, Spain
- ⁴³Departament de Genètica i Microbiologia. Universitat Autònoma de Barcelona, Cerdanyola
- ⁴⁴Instituto de Investigación Sanitaria de Aragón, Centro de Investigación Biomédica de Aragón (CIBA), Zaragoza, Spain
- ⁴⁵Facultad de Medicina, Universidad de Zaragoza, Zaragoza, Spain
- ⁴⁶Hospital General Universitario de Albacete, Spain
- ⁴⁷Servicio de Enfermedades Infecciosas, Hospital Clínic de Barcelona, Barcelona, Spain

Acknowledgements

This work was mainly funded by the Instituto de Salud Carlos III project COV20/00140, with additional funding by Spanish National Research Council project CSIC-COV19-021, Ministerio de Ciencia project PID2019-104477RB-I00, ERC StG 638553 and ERC CoG 101001038 to IC and BFU2017-89594R to FGC. MC is supported by Ramón y Cajal program from Ministerio de Ciencia and grants RTI2018-094399-A-I00 and Generalitat Valenciana (Regional Government) project SEJI/2019/011.

We gratefully acknowledge Hospital Universitari Vall d'Hebron, Instituto de Salud Carlos III, IrsiCaixa AIDS Research Lab and all the international researchers and institutions that submitted sequenced SARS-CoV-2 genomes to the GISAID's EpiCov™ Database (Supplementary Table 1), as an important part of our analyses have been made possible by the share of their work.

We also thank Unidad de Bioinformática y Estadística, Centro de Investigación Príncipe Felipe, for allowing us to use of the Computer Cluster to perform some of the bioinformatic analysis.

Data availability

All the genomic sequences used in the analyses are available in the GISAID database, and the accession numbers, originating and submission laboratories can be found in Supplementary Table 1. Sequencing data (fastq files) of the samples sequenced by the SeqCOVID-consortium have been deposited to the European Nucleotide Archive (ENA), and the corresponding accession numbers can also be found in Supplementary Table 1.

Code availability

The analysis pipeline used to map and analyze the sequences is available at <https://gitlab.com/fisabio-ngs/sars-cov2-mapping>.

References

1. Zhu N, et al. Brief report: A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med.* 2020; 382 :727. [PubMed: 31978945]
2. Spiteri G, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. *Eurosurveillance.* 2020; 25
3. Centro de Coordinación de Alertas y Emergencias Sanitarias. Enfermedad por el coronavirus, situación en España. 2020
4. Pollán M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *Lancet.* 2020; 396 :535–544. [PubMed: 32645347]
5. Ministerio de la Presidencia, R. C. las C. y. M. D. 2020. BOE-A-2020-3692. <https://www.boe.es/eli/es/rd/2020/03/14/463/con>
6. Instituto de Salud Carlos III, Spanish Government. COVID-19 reported cases in Spain. <https://cnevidisciiies/covid19/#ccaa>
7. Centro de Coordinación de Alertas y Emergencias Sanitarias, Ministerio de Sanidad. Enfermedad por el coronavirus (COVID-19). 2020. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Actualizacion_268_COVID-19.pdf
8. Grenfell BT, et al. Unifying the epidemiological and evolutionary dynamics of pathogens. *Science.* 2004; 303 :327–332. [PubMed: 14726583]
9. Volz EM, Kosakovsky Pond SL, Ward MJ, Leigh Brown AJ, Frost SDW. Phylodynamics of Infectious Disease Epidemics. *Genetics.* 2009; 183 :1421–1430. [PubMed: 19797047]
10. Vasylyeva TI, et al. Phylodynamics Helps to Evaluate the Impact of an HIV Prevention Intervention. *Viruses.* 2020; 12
11. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro Surveill.* 2017; 22
12. Callaway E. The coronavirus is mutating — does it matter? *Nature.* 2020; 585 :174–177. [PubMed: 32901123]
13. Kupferschmidt K. The pandemic virus is slowly mutating. But does it matter? *Science.* 2020; 369 :238–239. [PubMed: 32675355]
14. Morel B, et al. Phylogenetic analysis of SARS-CoV-2 data is difficult. *bioRxiv.* 2020; 2020.08.05.239046 doi: 10.1101/2020.08.05.239046
15. Worobey M, et al. The emergence of SARS-CoV-2 in Europe and North America. *Science.* 2020; 370 :564–570. [PubMed: 32912998]
16. Geoghegan JL, et al. Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand. *medRxiv.* 2020; doi: 10.1101/2020.08.05.20168930
17. Seemann T, et al. Tracking the COVID-19 pandemic in Australia using genomics. *Nat Commun.* 2020; 11 4376 [PubMed: 32873808]
18. Alm E, et al. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. *Eurosurveillance.* 2020; 25 2001410
19. Oude Munnink BB, et al. Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands. *Nat Med.* 2020; 26 :1405–1410. [PubMed: 32678356]
20. Candido DS, et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. *Science.* 2020; 369 :1255–1260. [PubMed: 32703910]
21. Guirao A. The Covid-19 outbreak in Spain A simple dynamics model, some lessons, and a theoretical framework for control response. *Infectious Disease Modelling.* 2020; 5 :652. [PubMed: 32869008]
22. Hyafil A, Morina D. Analysis of the impact of lockdown on the reproduction number of the SARS-Cov-2 in Spain. *Gac Sanit.* 2020; doi: 10.1016/J.gaceta.2020.05.003
23. Lurie MN, Silva J, Yorlets RR, Tao J, Chan PA. Coronavirus Disease 2019 epidemic doubling time in the United States before and during stay-at-home restrictions. *J Infect Dis.* 2020; 222 :1601–1606. [PubMed: 32738142]

24. Böhmer MM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *The Lancet Infectious Diseases*. 2020; 20 :920–928. [PubMed: 32422201]
25. Rambaut A, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nature Microbiology*. 2020; 5 :1403–1407.
26. Lai A, et al. Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic. *Viruses*. 2020; 12
27. Phylogenetic analysis of SARS-CoV-2 diversity in Europe (Italy). <https://nextstrain.org/groups/neherlab/ncov/italy>
28. Plante JA, et al. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature*. 2020 :1–6.
29. Volz EM, et al. Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity. *Cell*. 2020; doi: 10.1016/J.cell.2020.11.020
30. Korber B, et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell*. 2020; 182 :812–827. [PubMed: 32697968]
31. van Dorp L, et al. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. *Nat Commun*. 2020; 11 :1–8. [PubMed: 31911652]
32. Google. COVID-19 Community Mobility Reports. <https://www.google.com/covid19/mobility/>
33. Russell TW, et al. Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study. *The Lancet Public Health*. 2020; doi: 10.1016/S2468-2667(20)30263-2
34. Popa A, et al. Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. *Sci Transl Med*. 2020; doi: 10.1126/scitranslmed.abe2555
35. Lemieux J, et al. Phylogenetic analysis of SARS-CoV-2 in the Boston area highlights the role of recurrent importation and superspreading events. *medRxiv*. 2020; doi: 10.1101/2020.08.23.20178236
36. Hodcroft EB, et al. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. *Nature*. 2021; doi: 10.1038/s41586-021-03677-y
37. Argimón S, et al. Microreact: visualizing and sharing data for genomic epidemiology and phylogeography. *Microbial Genomics*. 2016; 2 e000093 doi: 10.1099/mgen.0.000093 [PubMed: 28348833]
38. Quick J. nCoV-2019 sequencing protocol. 2020; doi: 10.17504/protocols.io.bbmuik6w
39. artic-network. artic-network/artic-ncov2019. <https://github.com/artic-network/articncov2019>
40. Grubaugh ND, et al. An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar. *Genome Biol*. 2019; 20 :1–19. [PubMed: 30606230]
41. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. *Genome Biol*. 2014; 15 :1–12.
42. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics*. 2018; 34 :i884–i890. [PubMed: 30423086]
43. Ewels P, Magnusson M, Lundin S, Käller M. MultiQC: summarize analysis results for multiple tools and samples in a single report. *Bioinformatics*. 2016; 32 :3047–3048. [PubMed: 27312411]
44. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. *Euro Surveill*. 2017; 22
45. Wu F, et al. A new coronavirus associated with human respiratory disease in China. *Nature*. 2020; 579
46. Katoh K, Misawa K, Kuma K-I, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res*. 2002; 30 :3059–3066. [PubMed: 12136088]
47. De Maio N, et al. Issues with SARS-CoV-2 sequencing data. 2020
48. Lanfear R. A global phylogeny of SARS-CoV-2 sequences from GISAID. *Zenodo*. 2020; doi: 10.5281/ZENODO.3958883

49. Nguyen L-T, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. *Mol Biol Evol.* 2015; 32 :268–274. [PubMed: 25371430]
50. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v4: recent updates and new developments. *Nucleic Acids Res.* 2019; 47 :W256–W259. [PubMed: 30931475]
51. Kumar S, Stecher G, Peterson D, Tamura K. MEGA-CC: computing core of molecular evolutionary genetics analysis program for automated and iterative data analysis. *Bioinformatics.* 2012; 28 :2685–2686. [PubMed: 22923298]
52. QGIS Development Team. QGIS Geographic Information System. 2020
53. Rambaut A, Lam TT, Max Carvalho L, Pybus OG. Exploring the temporal structure of heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol.* 2016; 2 vew007 [PubMed: 27774300]
54. Bouckaert R, et al. BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis. *PLoS Comput Biol.* 2019; 15 e1006650 [PubMed: 30958812]
55. Grummer JA, Bryson RW, Reeder TW. Species delimitation using Bayes factors: simulations and application to the *Sceloporus scalaris* species group (Squamata: Phrynosomatidae). *Syst Biol.* 2014; 63
56. Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior Summarization in Bayesian Phylogenetics Using Tracer 1.7. *Systematic Biology.* 2018; 67 :901–904. [PubMed: 29718447]
57. Rambaut A. FigTree. 2016
58. Stadler T, Kühnert D, Bonhoeffer S, Drummond AJ. Birth–death skyline plot reveals temporal changes of epidemic spread in HIV and hepatitis C virus (HCV). *Proc Natl Acad Sci U S A.* 2013; 110 :228–233. [PubMed: 23248286]
59. He X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med.* 2020; 26 :672–675. [PubMed: 32296168]
60. R Core Team. R: A language and environment for statistical computing. 2017
61. Paradis E, Schliep K. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. *Bioinformatics.* 2019; 35 :526–528. [PubMed: 30016406]
62. Wang L-G, et al. Treeio: An R Package for Phylogenetic Tree Input and Output with Richly Annotated and Associated Data. *Molecular Biology and Evolution.* 2020; 37 :599–603. [PubMed: 31633786]
63. Microsoft Corporation and Steve Weston. doParallel: Foreach Parallel Adaptor for the ‘parallel’ Package.
64. Microsoft Corporation and Steve Weston. foreach: Provides Foreach Looping Construct.
65. Hijmans RJ, Williams E, Vennes C. Spherical Trigonometry.
66. Pebesma E, Rundel C, Teucher A. lwgeom: Bindings to Selected ‘liblwgeom’ Functions for Simple Features. 2020
67. Bivand, RS, Pebesma, E, Gómez-Rubio, V. Applied Spatial Data Analysis with R. Springer Science & Business Media; 2013.
68. Pebesma E. Simple Features for R: Standardized Support for Spatial Vector Data. *The R Journal.* 2018; 10 :439.
69. Bivand R, et al. rgeos: Interface to Geometry Engine - Open Source (‘GEOS’).
70. Wilkinson L. ggplot2: Elegant Graphics for Data Analysis by WICKHAM, H. *Biometrics.* 2011; 67 :678–679.
71. Instituto de Salud Carlos III, Spanish Government. COVID-19: Data and documentation.




Figure 1. SARS-CoV-2 genomes sequenced from Spain.

a. Distribution of sequenced samples (blue) versus confirmed cases in Spain (grey) by date. Country lockdown measures were in effect from 14th March to 14th May 2020.

b. Distribution of the sequenced samples across Spain was plotted in Microreact. These data can be explored with more detail in the Microreact webpage (<https://microreact.org/showcase>) loading the Supplementary Data 1 files. The size of each piechart correlates with the number of sequences collected in the corresponding area. Each color corresponds to a specific Pango lineage, as detailed in Extended Data Figure 1 (light yellow and green correspond to lineage A, all the others are lineage B). The map image was extracted from the Microreact visualization³⁷.

c. Distribution of major SARS-CoV-2 clades during the first stages of the pandemic (before 1st April 2020), in those European countries with more than 50 sequences deposited in GISAID as of 13th November 2020.

d. Global maximum likelihood phylogeny constructed with 32,416 sequences, placement of Spanish samples is indicated in red.

e. New and accumulated introductions to Spain. Lower-bound introduction estimates were defined as the date of the likely infection of the first case in a cluster (14 days before symptom onset).

f. Estimated international origin of SARS-CoV-2 introductions based on phylogenetic data; in color, those countries with a likely contribution larger than 10%.




Figure 2. Inferred introduction times and expansion of SECs.

a. Maximum likelihood phylogenetic tree of Spanish sequences indicating the identified Spanish Epidemic Clades (SECs, inner circle), the Pango lineage (middle circle) and the NextStrain clade (outer circle). **b.** Range of dates for each ‘candidate transmission cluster’ identified within the SECs, and the most probable origin date (14 days before the first documented case) **c.** Time of the Most Recent Common Ancestors (MRCA) of each SEC is plotted, including the 95% HPD interval (High Posterior Density). First collected sample, and whether it is Spanish or non-Spanish, is indicated. **d.** SEC dispersion through the different regions of the country. Some SECs are restricted to one or two regions, while others have expanded through the complete territory.




Figure 3. SEC8 epidemiological success and impact of mobility restrictions.

a. Maximum likelihood phylogeny with all the strains of SEC8. Samples with epidemiological evidence about their origin are marked in the tree. In red, cases imported from different events in Italy. In orange, secondary cases originated from one of the cases introduced from Italy (also marked with blue arrows). In purple, cases related to a large funeral in La Rioja. Green stars mark potential superspreading events of more than 10 sequences sharing at least one clade-defining SNP. **b.** Contribution of SEC8 to the total of samples sequenced over time. The horizontal red line marks the start of the Spanish lockdown, on 14th March 2020. **c.** Phylodynamic estimates of the reproductive number (R_e) of SEC8. The X axis represents time, from the origin of the sampled diversity of SEC8 to the date of the last collected genome on 16th May 2020. The blue dotted line shows the posterior value of the timing of the most significant change in R_e , around 9th March 2020 [95% HPD: 8–10th March]. The Y axis represents R_e , and the violin plots show the posterior distribution of this parameter before and after the change time in R_e , with a mean of 3.14 [95% HPD: 2.71–3.57] and 0.23 [95% HPD: 0.15–0.32] before and after the change time respectively. The phylogenetic tree in the background is a maximum clade credibility tree with the tips colored according to whether they were sampled before or after 9th March 2020. The lower whisker, higher whisker, center and bounds of each box plot refers to quartile 1–1.5 interquartile range, quartile 3 + 1.5 interquartile range, mean, first and third quartiles of the data. Individual points are outliers (values lower than quartile 1–1.5 interquartile range and higher than quartile 3 + 1.5 interquartile range). Boxplot was constructed with all the Spanish sequences in SEC8 (N=636).